Drug, bio-affecting and body treating compositions inventions

20090263317 - Method of screening the activity of the smoothened receptor to identify theraputic modulation agents or diagnose disease: The invention relates to a screening method for the Smoothened receptor for testing compositions as potential Smoothened receptor ligands, either agonist or antagonist activity, by use of an arrestin-reporter molecule conjugate. It also relates to testing cells and individuals by administering a smoothened receptor ligand-reporter molecule conjugate and observing locations... Agent: Passe' Intellectual Property, LLC

20090263318 - Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer: A novel gene 254P1D6B and its encoded protein, and variants thereof, are described wherein 254P1D6B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 254P1D6B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 254P1D6B gene or... Agent: Agensys C/o Morrison & Foerster LLP

20090263319 - Methods and compositions for treating postoperative pain comprosing ketorolac: Methods and compositions are provided for reducing, treating or preventing postoperative pain or inflammation in a patient in need of such treatment, the methods and compositions comprising administering one or more biodegradable drug depots comprising a therapeutically effective amount of ketorolac or pharmaceutically acceptable salt thereof to a target tissue... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263320 - Peptide-based compounds: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.... Agent: Ge Healthcare, Inc.

20090263321 - Compositions and methods for treating post-operative pain using clonidine and bupivacaine: Effective treatments of pain that accompanies post-operative surgeries are provided. Through the administration of an effective amount of a combination of bupivacaine and clonidine at or near a target site, one can alleviate or prevent pain. This administration of bupivacaine and clonidine or pharmaceutically acceptable salts thereof is particularly useful... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263322 - Octahydro-indolizine and quinolizine and hexahydro-pyrrolizines: The invention features substituted fused bicyclic compounds, pharmaceutical compositions containing them, and methods of using them to treat or prevent histamine-mediated diseases and conditions.... Agent: Philip S. Johnson Johnson & Johnson

20090263323 - Novel means and methods for the treatment of hearing loss and phantom hearing: This invention relates to a method of identifying a modulator of an NADPH oxidase, whereby said modulator is suitable as a lead compound and/or as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing, the method comprising the steps of (a) contacting a test compound with... Agent: Fulbright & Jaworski L.L.P.

20090263324 - Animal model with induced arrhythmia: Provided are a model animal physiologically similar to humans, enabling a highly reproducible evaluation of the onset of drug-induced long QT syndrome, a method of generating the same, and an evaluating method using the same. A proarrhythmia model animal of a monkey, prepared by ablating the atrioventricular node; the foregoing... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090263325 - Method and apparatus for the dissolution and filtration of a hyperpolarized agent with a neutral dissolution media: Methods and apparatuses that facilitate dissolving a hyperpolarized agent within a polarizer and transporting it to a receiver is provided. The methods include delivering water to a hyperpolarized agent contained within a polarizer, forming a hyperpolarized aqueous solution, transporting the aqueous solution through a fluid path system out of the... Agent: General Electric Company Global Research

20090263327 - Minimally invasive physiological function monitoring agents: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090263326 - Nano-scale contrast agents and methods of use: Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution.... Agent: Benesch, Friedlander, Coplan & Aronoff LLP Attn:IPDepartment Docket Clerk

20090263331 - Multifunction nanoconjugates for imaging applications and targeted treatment: The present invention relates to nanoconjugates. In particular, the present invention provides nanoconjugates for diagnostic (e.g., imaging), research, and clinical (e.g., targeted treatment) applications.... Agent: Casimir Jones, S.c.

20090263332 - Polymer particle containing paramagnetic metal compound: wherein R1 represents hydrogen atom or methyl group; R2 represents a hydrogen atom or a methyl group; A represents —(CH2)2N+(CH3)3 or the like; and B represents oxygen atom, sulfur atom, —CH2—, or —NH—; and R4 represents hydrogen atom, an optionally substituted alkyl group, or an optionally substituted aryl group, which... Agent: Young & Thompson

20090263329 - Cell labeling with perfluorocarbon nanoparticles for magnetic resonance imaging and spectroscopy: Methods of obtaining cells internally labeled with perfluorocarbon nanoparticles suitable for magnetic resonance imaging and spectroscopy are disclosed. Also disclosed are methods for obtaining magnetic resonance imaging data from labeled under clinically relevant scan times and field strengths. Finally, the application further discloses methods of specifically detecting and distinguishing magnetic... Agent: Thompson Coburn LLP Attn: Richard E. Haferkamp

20090263330 - Gas-filled microvesicles with polymer-modified lipids: Image enhancing contrast agents for use in diagnostic and/or therapeutic methods, particularly in the form of gas-filled microvesicles, with enhanced stability. The gas-filled microvesicles are stabilized by a layer of amphiphilic material and comprise from 0.15% to 1.0% by moles of a lipid bearing a hydrophilic polymer. The lipid bearing... Agent: Bracco Research Usa Inc.

20090263328 - Fluorescence observation apparatus and fluoroscopy method: A site of interest to be observed is clearly observed in an image during fluoroscopy of a small laboratory animal, even when the fluorescence is extremely low. The invention provides a fluorescence observation apparatus including a light source that emits excitation light; an optical system that irradiates an image-acquisition site... Agent: Scully Scott Murphy & Presser, PC

20090263334 - Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals: Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat cognitive disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such conditions.... Agent: Borson Law Group, PC

20090263333 - Pharmaceutical compounds and compositions: The invention provides three polymorphic forms of crystalline levosalbutamol sulphate designated herein as Forms I, II and III. Crystalline levosalbutamol sulphate Form I is characterised by a powder XRD pattern with peaks at 10.8, 11.9, 13.0, 18.3, 28.5±0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form II is characterised by a... Agent: Conley Rose, P.C.

20090263335 - Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease: The present invention relates to methods and compositions for prevention of graft rejection in lung transplant recipients and for treatment of subjects with pulmonary disorders. Specifically, the methods and compositions of the invention provide a means for inhibiting immune response mediated inflammatory processes in the lungs. The method of the... Agent: Baker Botts L.L.P.

20090263337 - Detersive compositions containing hydrophobic benefit agents pre-emulsified using sub-micrometer-sized insoluble cationic particles: A cationic oil-in-water emulsion, for addition to detersive compositions, comprising hydrophilic cationic polymers, a surface-active, anionic polymer that is capable of adsorbing at an air-water interface or an oil-water interface and/or is oil-soluble, and a hydrophobic benefit agent in the oil phase made by adding the benefit agent to a... Agent: Marshall, Gerstein & Borun LLP

20090263336 - Novel pyran derivatives and their preparation: c

20090263338 - Nail varnish: Nail varnish composition in the form of an emulsion containing one or more water-soluble or water-dispersible polymers obtained from acrylamido-2-methylpropanesulphonic acid (or AMPS) or from one of its salts and from water-soluble monomers having ethylenic unsaturation(s) as gelling agent. Makeup method employing the composition. Dried films of the nail varnish.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090263339 - Agent for external application to the skin: The present invention has an object to provide an agent for suppressing melanin production and/or inhibiting elastase activity containing a plant extract as an effective substance with high safety and acceptable levels of stability and odor or sediment formation and an agent for external application to the skin comprising the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090263340 - Cosmetic compositions: The present invention relates to cosmetic or dermatological compositions comprising salicylic acid, optionally substituted salicylic acid and/or derivatives thereof and ascorbic acid and/or derivatives thereof in a cosmetically acceptable carrier. The salicylic acid, optionally substituted salicylic acid and/or derivatives thereof serve as skin penetration enhancer for the ascorbic acid and/or... Agent: Nixon & Vanderhye, PC

20090263341 - Soft anticholinergic esters: wherein R1 and R2 are both phenyl or one of R1 and R2 is phenyl and the other is cyclopentyl; R is C1-C8 alkyl, straight or branched chain; and X− is an anion with a single negative charge; and wherein each asterisk marks a chiral center; said compound having the... Agent: Buchanan, Ingersoll & Rooney PC

20090263342 - Non-lathering personal care composition in the form of an article: A non-lathering personal care article in the form of a porous dissolvable solid structure, comprising: from about 0% to about 10% ionic surfactant; from about 1% to about 60% of a non-surfactant cosmetic active; from about 15% to about 70% polymeric structurant, wherein the polymeric structurant has a weighted average... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090263343 - Deodorized cloth and method for deodorizing cloth: Disclosed is a deodorized cloth which is produced by applying a deodorizing agent comprising active carbon and an amine compound in two layers on a cloth, thereby providing a durable deodorizing property against any type of odor to the cloth. Also disclosed is a method for deodorization processing of a... Agent: Kirschstein, Israel, Schiffmiller & Pieroni, P.C.

20090263344 - Perfume compositions: Perfume compositions effective against urine malodour and having a low odour, comprise between 20% and 50% of perfume ingredients comprising at least 15% by-weight of N-ethyl-N-(3-methylphenyl) propanamide.... Agent: Norris, Mclaughlin & Marcus

20090263345 - Otic compositions for the treatment of infections of the internal and external ear in mammals: Disclosed herein compositions including povidone-iodine (PVP-I) useful in the treatment of acute and chronic bacterial, viral and fungal infections of the internal, middle and external ear of mammals, including humans.... Agent: Morgan, Lewis & Bockius LLP

20090263346 - Systems and methods for delivery of drugs: Systems and methods for delivering drugs. Crystalline polymeric systems, referred to as CYC carriers, are associated with the drugs, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively... Agent: Bell & Associates

20090263347 - Analysis of amino acid copolymer compositions: Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. In some cases, the methods entail treating the... Agent: Fish & Richardson PC

20090263348 - Nucleic acids encoding multimeric fusion proteins of tnf superfamily ligands: A method for constructing stable bioactive fusion proteins of the difficult to express turn or necrosis factor superfamily (TNFSF), and particularly members CD40L (CD 154) and RANKL/TRANCE, with collecting, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural... Agent: Dla Piper LLP (us)

20090263350 - Cosmetic and dermatological methods: The present invention relates to cosmetic and dermatological methods for treating cellulite, reducing signs of aging skin, and treating stretch marks, the methods comprising applying/administering to the skin of a subject in need thereof the compositions comprising interleukin-1 alpha.... Agent: Notaro & Michalos P.C.

20090263349 - Methods and compositions for inhibiting angiogenesis: The present invention relates to a method of inhibiting angiogenesis in a biological system. The method includes administering to the biological system an effective amount of a steroid saponin.... Agent: Klarquist Sparkman, LLP

20090263352 - Methods for treating viral infection using il-28 and il-29 cysteine mutants: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20090263351 - Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid... Agent: Wyeth/finnegan Henderson, LLP

20090263353 - Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles: t

20090263354 - Compositions and sirnas for inhibiting c/ebpbeta: The invention relates to C/EBPβ and modulation of cell resistance or sensitivity to triggers of cell death. More particular, it provides pharmaceutical compositions and siRNAs for inhibiting C/EBPβ thus decreasing resistance or enhancing sensitivity of cancer cells to a cancer therapy.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090263355 - Deamidated interferon-beta: Interferon-β protein analogs in which the asparagine at position 25, numbered in accordance with native interferon-β, is deamidated exhibit a biological activity of native human interferon-β at an increased level and do not require HA for protein stabilization. The deamidated product is suitable for large scale manufacturing for incorporation in... Agent: Novartis Corporate Intellectual Property

20090263364 - Method and constructs for delivering double stranded rna to pest organisms: The present invention relates in generally to RNAi and its use in gene silencing. In particular, the present invention relates to methods and constructs for delivering double stranded RNA (dsRNA) to pest organisms.... Agent: Wolf Greenfield & Sacks, P.C.

20090263365 - Methods and compositions for transforming dendritic cells and activating cells: Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates T cells against MHC class I-antigen targets. Kits, assays and therapeutics are based upon the activation of T cells by... Agent: Townsend And Townsend And Crew, LLP

20090263356 - Anti-angiogenic composition comprising grain-derived component as active ingredient: It is an object of the invention to provide a composition with an excellent action of inhibiting vascularization, as prepared by a simple method suitable for actual production from an inexpensive, relatively readily available material without any problematic safety profile at an industrial scale without any complicated purification step. The... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090263366 - Effects of probiotics on humans and animals under environmental or biological changes: An exemplary embodiment providing one or more improvements includes probiotic compositions comprising probiotic microorganisms with dried vegetable, fruit, cereal, or herb powder. Feeding human or animals either having biological or environmental changes with probiotic compositions has a positive effect in relieving the changes. Positive effects has been demonstrated in humans,... Agent: William S Ramsey, Esq

20090263363 - Compositions and methods for treating bone formation disorders: The present invention relates to compositions and methods for the detecting, treating, and empirically investigating disorders associated with bone formation (e.g., osteoporosis). In particular, the present invention provides compositions and methods for using maspin and targets of maspin in the diagnosis, treatment, and empirical investigation of disorders associated with bone... Agent: Casimir Jones, S.c.

20090263362 - Fertility enhancement using lipid carriers and bioactive molecules: The invention relates to a composition and method for enhancing fertilization. Fertilization enhancement is achieved by effectively delivering bioactive molecules with a lipid anchor (GPI-linked proteins) to the surface of epididymal or ejaculated sperm. The process may be facilitated or promoted in the presence of Clusterin/APOJ, a well-known lipid carrier.... Agent: Mccarter & English, LLP Wilmington Basil S. Krikelis

20090263361 - Human trophoblast stem cells and use thereof: Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive... Agent: Wilson, Sonsini, Goodrich & Rosati

20090263358 - Method for treating multiple myeloma: The present invention relates to methods for the treatment of multiple myeloma. More particularly, the present invention relates to a method for inducing apoptosis in myeloma cells by administration of a K121-like antibody.... Agent: Bozicevic, Field & Francis LLP

20090263360 - Neuronal progenitors from feeder-free human embryonic stem cell culture: The present invention relates to methods for producing feeder cell-free neuroprogenitor cells (preferably adherent) from embryonic stems cells, preferably human embryonic stem cells, the feeder cell-free neuroprogenitor cells, preferably human cells themselves, as well as methods for producing feeder cell-free samples of neuronal cells, preferably adherent human neuronal cells and... Agent: Coleman Sudol Sapone, P.C.

20090263359 - Particulate delivery vehicles for embryoid bodies: The present invention provides a vehicle for delivering various chemicals, compositions and proteins to stem cells and embryoid bodies. The vehicle may be biocompatible and biodegradable polymer microparticles. Typically the particles will contain at least a growth factor for delivery to the embryoid bodies, and generally the growth factor induces... Agent: Choate, Hall & Stewart LLP

20090263357 - Therapeutic reprogramming, hybrid stem cells and maturation: Therapeutically programmed cells and methods for making such cells are provided. Therapeutically programmed cells are stem cells which have been matured such that they represent either a more differentiated state or a less differentiated state after contact with stimulatory factors. The therapeutically reprogrammed cells are suitable for cellular regenerative therapy... Agent: K&l Gates LLP

20090263367 - Composition and method for promoting internal health and external appearance: The present invention relates to a new composition comprising substances that promote DNA repair, reduce body fat levels and increase lean body mass and that decrease wrinkle appearance and/or improvement in skin surface. In some aspects, the composition of the present invention include resveratrol, forskohlin and astaxanthin. In another aspect... Agent: Miller Thomson LLP

20090263369 - Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof: The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as... Agent: Jones Day

20090263368 - Genetic variations associated with psychiatric disorders: The present invention relates to a method for determining likelihood of an individual of developing a psychiatric disorder. More particularly, the method of the invention is based on the identification of genetic variations in genes involved in the modulation of melatonin and their consequences on such pathway for the determination... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090263370 - Methods for treating tachykinin-mediated diseases with cholinesterase: Methods for treating or preventing a tachykinin-mediated disease, a skin disorder, or a symptom thereof in a mammal by administering to a mammal in need thereof cholinesterase or a pharmaceutical composition of cholinesterase.... Agent: Matthias Scholl

20090263372 - Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of... Agent: Kristina M. Grasso Kristina M. Grasso, Esq. PLLC

20090263371 - Use polysaccharides for promotion of enzymatic activity: This disclosure provides methods and compositions for the promotion of enzymatic activity of Target Enzymes, including but not limited to oligosaccharide/polysaccharide enzymes, protein enzymes, polynucleotide enzymes. The methods involve use of a non-naturally occurring polysaccharide (including but not limited HES) for promoting the enzymatic activity of an enzyme in liquid... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090263373 - Non-neurotoxic plasminogen activating factors for treating of stroke: The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090263374 - Method of preventing and treating brain infarction: The present invention is intended to clarify the relationship between PAR-2 and cerebral infarction and thereby provide an efficient method of preventing and treating cerebral infarction, as well as a pharmaceutical composition therefore. Namely, the present invention relates to a method of preventing and treating cerebral infarction by activating PAR-2... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090263376 - Breaking immunological toterance with a genetically encoded unnatural amino acid: The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against... Agent: Quine Intellectual Property Law Group, P.C.

20090263377 - Il-32b-targeted diagnosis and therapy: Methods for the diagnosis and treatment of IL-32β over-expressing cancers are provided. Also provided are methods for the treatment of wounds, hair loss and the promoting and/or restoration of hair growth utilized IL-32β antagonists. Finally, a sepsis model utilizing IL-32β is provided, as are methods for treating sepsis and inflammation... Agent: Fulbright & Jaworski L.L.P.

20090263378 - Methods of identifying anti-inflammatory compounds: A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090263379 - Monoclonal antibodies for inhibition of laminin-8 expression to inhibit human gliomas: Using gene array technology, we observed that an increase of the alpha-4 chain-containing Laminin-8 correlated with poor prognosis for patients with brain gliomas. We established that inhibition of Laminin-8 expression by a new generation of highly specific and stable antisense oligonucleotides (Morpholino™) against chains of Laminin-8 could slow or stop... Agent: Davis Wright Tremaine LLP/los Angeles

20090263375 - Novel poly(a) polymerase: The present invention relates to novel poly(A) polymerases and their use in the treatment of diseases, disorders and conditions. More specifically, the poly(A) polymerases of the present invention include polymerases which are directly modulated by components of the phosphoinositide signaling pathway. Such components may include phosphatidylinositol phosphate kinases and phosphoinositide... Agent: Wisconsin Alumni Research Foundation (warf)

20090263380 - Anti-idiotypic antibodies neutralizing the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly... Agent: Cermak Kenealy Vaidya & Nakajima LLP

20090263381 - Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease: A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anti-IgE antibody for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and... Agent: Wilson, Sonsini, Goodrich & Rosati

20090263384 - Agents for suppressing the induction of cytotoxic t cells: The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6... Agent: Fish & Richardson PC

20090263391 - Antibodies that bind to epha2 and methods of use thereof: Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed.... Agent: Morrison & Foerster LLP

20090263383 - Antibodies to angiogenesis inhibiting domains of cd148: The present invention provides compositions and methods relating to anti-CD148 receptor antibodies. Methods provided include inhibiting angiogenesis and, thereby, vascularization of solid tumors in human patients. The present invention also provides compositions and methods for in vivo imaging of tumors expressing CD148. Compositions of the invention include: anti-CD148 antibodies, antigen... Agent: Amgen Inc. Law Department

20090263385 - Breast carcinoma treatment method: The instant invention is an in-vivo treatment method directed against living epithelial cells in the human breast, and uses a modified ductal lavage technique to infuse a purposely formulated treatment fluid into pre-chosen individual ducts in the human breast for reaction with such epithelial cells as then are present within... Agent: David Prashker P.C.

20090263386 - Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency.... Agent: Winston & Strawn LLP Patent Department

20090263390 - Method of treating cancer by co-administration of anticancer agents: The present invention relates to a method of treating cancer by co-administration of an effective amount of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin -2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide and an effective amount of one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or a retuximab-containing... Agent: Sughrue Mion, PLLC

20090263388 - Methods of preventing or treating cardiovascular, cerebrovascular and thrombotic disorders with tumor necrosis factor antagonists: A method of treating or preventing a cardiovascular and/or a cerebrovascular disorder in an individual is disclosed. Also disclosed is a method for treating and/or preventing a thrombotic disorder in an individual. Further disclosed is a method of decreasing plasma fibrinogen in an individual.... Agent: Cooper & Dunham, LLP

20090263387 - Neutralization of gm-csf for the treatment of heart failure: This invention relates to methods of treating a patient suffering from heart failure, or a patient at risk for heart failure, using a GM-CSF antagonist.... Agent: Townsend And Townsend And Crew, LLP

20090263382 - Stable and soluble antibodies inhibiting tnf alpha: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis... Agent: Marshall, Gerstein & Borun LLP

20090263389 - Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection: Effective use of a TGF-β antagonist to treat or to prevent loss of transplant function is described herein. Use of a TGF-β antagonist is demonstrated to effectively prevent loss of organ function in a host due to chronic rejection in which TGF-β-mediated fibroproliferation is a characteristic. Expression in situ of... Agent: Genzyme Corporation Legal Department

20090263392 - Methods of modifying antibodies for purification of bispecific antibodies: The present inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column based on the difference in isoelectric points between the H chains of two types of antibodies, wherein the difference is introduced by modifying the amino acids present on the surface of the antibody variable regions of... Agent: Fish & Richardson PC

20090263394 - A34 and a33-like 3 dna protein, antibodies thereto and methods of treatment using same: Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a... Agent: Crowell & Moring LLP Intellectual Property Group

20090263393 - Methods of using(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4 -oxo-1-(2-thiazolyl)- 1,8-naphthyridine-3-carboxylic acid for treatment of cancer: Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for... Agent: Jones Day

20090263395 - Genes and polypeptides relating to breast cancers: The present application provides novel human genes B1194, A2282V1, A2282V2, and A2282V3 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer.... Agent: Townsend And Townsend And Crew, LLP

20090263396 - Inhibitors of t-darpp for use in combination anti-cancer therapies: The present invention relates to an improved anti-HER2/Neu therapy comprising co-administration of an inhibitor of t-DARPP activity. In addition, inhibitors of t-DARPP can act as a monotherapy against cancers that express elevated t-DARPP activity, including elevated t-DARPP levels, or in combination with chemo- or radiotherapeutic anti-cancer treatments drugs.... Agent: Fulbright & Jaworski L.L.P.

20090263397 - Combination anti-cancer therapy: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor of Formula... Agent: Osi Pharmaceuticals, Inc.

20090263399 - Method for establishing the sensitivity of tumours to capecitabin and test kit: e

20090263400 - Osteoporosis associated markers and methods of use thereof: Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.... Agent: Marshall, Gerstein & Borun LLP

20090263398 - Pharmaceutical combinations: The invention provides a combination comprising an ancillary compound and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R1-A-NR4— or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C═O, NR9(C═O) or 0(C═O) wherein... Agent: Heslin Rothenberg Farley & Mesiti PC

20090263402 - Growth differentiation factor-11: A transgenic non-human animal of the species selected from the group consisting of avian, bovine, ovine and porcine having a transgene which results in disrupting the production of and/or activity of growth differentiation factor-11 (GDF-11) chromosomally integrated into the germ cells of the animal is provided. Also provided are methods... Agent: Dla Piper LLP (us)

20090263401 - Uses of il-174 antagonists for inhibiting a th2 immune response: Agonists or antagonists of cytokine designated IL-174, and various methods of their use are provided. In particular, the methods make use of facts that many activities of the IL-174 cytokine are described.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090263403 - Mammalian cell membrane proteins; related reagents: The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use.... Agent: Schering-plough Biopharma Legal Department

20090263404 - Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor: Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor,... Agent: Law Office Of John K. Pike, PLLC

20090263407 - Cationic lipids and uses thereof: Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090263405 - Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods: The present invention provides a CpG oligonucleotide prodrug that includes a thermolabile substituent on at least one nucleotide thereof. The present invention also provides compositions that include a carrier and a therapeutically effective amount of at least one CpG oligonucleotide prodrug. The present invention further provides therapeutic methods of using... Agent: Leydig, Voit & Mayer, Ltd.

20090263408 - Formulation and presentation of medicaments: A medicament package (10,30) comprises a vessel (12,32) adapted to hold a quantity of a liquid vehicle. The vessel (12,32) has an opening formed therein, to which opening is bonded a deformable enclosure (18,38). A medicament container (20) that contains a unit dose of a medicament is received within the... Agent: Woodling, Krost And Rust

20090263406 - Jy-1 regulation of granulosa cell function and early embryonic development in cattle: The present invention provides compositions and methods for regulating fertility in mammals. In general, the invention relates to a novel protein produced by oocytes named JY-1, and nucleic acids encoding the JY-1 protein, for controlling folliculogenesis and early embryonic development, particularly in monoovulatory species. In particular, the present invention provides... Agent: Peter G. Carroll Medlen & Carroll, LLP

20090263409 - Cancer antigen peptide formulations: The invention relates to water-in-oil emulsions which comprise as an effective ingredient either one or both of peptides selected from the group consisting of a peptide having an amino acid sequence of Cys Met Thr Trp Asn Gln Met Asn Leu (SEQ ID NO: 2), and a peptide having an... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090263411 - Compositions, splice variants and methods relating to ovarian specific genes and proteins: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of... Agent: Kathleen A. Tyrrell Licata & Tyrrell P.C.

20090263410 - Use of tgf-b1 inhibitor peptides in the preparation of an immune response modulating agent: The present invention relates to the use of a peptide inhibiting TGF-β1 selected from: peptide p144 whose sequence corresponds to SEQ ID NO: 1, peptide p17 whose sequence corresponds to SEQ ID NO: 2, a peptide which has at least 90% homology therewith, or fragments of the above, in the... Agent: Moore & Van Allen PLLC

20090263412 - Non-splicing variants of gp350/220: Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use... Agent: Medimmune, LLC Patrick Scott Alban

20090263413 - Immunostimulatory oligonucleotides and use thereof in pharmaceuticals: A novel immunostimulatory oligonucleotide by which an IFN-inducing activity is enhanced and an inflammatory cytokine-inducing activity is reduced, and a pharmaceutical containing the same, and an application thereof are provided. That is, the present invention provides the immunostimulatory oligonucleotide composed of a base sequence represented by a formula: 5′-(G)MPXCGYQ(G)N-3′ (X... Agent: Birch Stewart Kolasch & Birch

20090263414 - Bifunctional protein anchors: The invention relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allows the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional... Agent: Traskbritt, P.C.

20090263415 - Composition for scalp and hair of scalp: An object of the present invention is to provide scalp and hair of scalp composition which realizes hair growing, hair growth or the like by arranging the scalp environment without inhibiting the function of sebaceous membrane and dark cell (superficial type cell) of scalp. To achieve the object, the present... Agent: Ladas & Parry LLP

20090263416 - Reduction of antibiotic resistance in bacteria: In one aspect of the present invention, a method is provided for reducing or eliminating antibiotic resistance in bacteria, comprising exposing the bacteria to a composition comprising a yeast cell wall preparation in an amount effective for reducing or eliminating resistance of the bacteria to at least one antibiotic. In... Agent: King & Schickli, PLLC

20090263417 - Multi-subtype fiv vaccines: The subject invention pertains to novel methods and compositions for protecting cats from infection by a broad range of FIV strains using a multi-subtype FIV vaccine. Multi-subtype FIV vaccines comprising either cell free whole virus or cell lines infected with viruses are described. Methods for vaccinating cats with the subject... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090263419 - Live attenuated bacterial vaccine: A live, attenuated bacterium of the genus Escherichia, Yersinia or Salmonella, that does not have a functional tRNA5leu, and vaccines comprising the live, attenuated bacterium.... Agent: Intervet/schering-plough Animal Health

20090263418 - Means and methods for manipulating sequential phagolysomalcytosolic translocation of mycobacteria, and uses thereof: Mycobacteria such as M. tuberculosis and M. leprae are considered to be prototypical intracellular bacilli that have evolved strategies to enable growth in the intracellular phagosomes of the host cell. By contrast, we show that lysosomes rapidly fuse with the virulent M. tuberculosis and M. leprae— containing phagosomes of human... Agent: Rissman Hendricks & Oliverio, LLP

20090263420 - Virus-like particles as vaccines for paramyxovirus: The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an... Agent: Peter G. Carroll Medlen & Carroll, LLP

20090263421 - Cellular vaccine: The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid molecule encoding an antigenic component thereof, wherein the T... Agent: Dann, Dorfman, Herrell & Skillman

20090263423 - Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc): This invention relates to a method for vaccination which is effective for eliciting an enhanced antigen-specific immune response in a mammal, fish or bird. The method is particularly effective for protecting a mammal, fish or bird from a disease including cancer, a disease associated with allergic inflammation, or an infectious... Agent: Dla Piper LLP (us)

20090263422 - Influenza vaccine: The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090263424 - Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090263425 - Methods of stimulating an immune response against prostate specific antigen: The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for... Agent: Leydig, Voit & Mayer, Ltd.

20090263426 - Methods for treating headache: A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the... Agent: Allergan, Inc.

20090263427 - Vaccines for mycoplasma bovis and methods of use: The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of... Agent: Kenyon & Kenyon LLP

20090263428 - Artificial lymph node for treating cancer: A method of producing an artificial lymph node capable of inducing cancer antigen-specific immune responses, comprising the following steps: (a) a step for immunizing a non-human animal using a cancer antigen and an adjuvant capable of inducing cellular immunity; and (b) a step for transplanting an artificial lymph node material... Agent: Leydig Voit & Mayer, Ltd

20090263429 - Method of preparing a hydrogel: A method of preparing a hydrogel comprises: (i) reacting a first molecule comprising a carboxylic acid group and second molecule comprising an amine group or an alcohol group with a hydrolase enzyme to form a product comprising an amide bond or ester bond, wherein the hydrolase enzyme would normally catalyse... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090263430 - Multilayer silk protein films: The present invention is directed to a method of forming multilayer silk protein films and a multilayer film obtained therefrom. The invention is further directed to various materials, products and compositions containing said multilayer film and to the use of Said multilayer film in several applications.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090263431 - Polyurethane foams for wound management: The invention relates to a process for producing polyurethane foams for wound management wherein a composition containing a polyurethane dispersion and specific coagulants is frothed and dried.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090263432 - Stable combinations of amlodipine besylate and benazepril hydrochloride: The present invention provides a pharmaceutical composition comprising benazepril and amlodipine wherein the benazepril and the amlodipine are in physical contact with one another, and methods for making the same.... Agent: Kenyon & Kenyon LLP

20090263435 - Compositions and methods for minimizing and/or reducing the appearance of defects around eyes: The invention relates to compositions comprising at least one xanthine compound, preferably further comprising at least one agent which acts on capillary circulation and/or at least one natural moisturizing agent, which can be used to treat, or to reduce and/or minimize the appearance of, defects such as dark circles, bags... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090263433 - Cosmetic composition: Provided are a cosmetic composition which is an O1/W/O2 emulsion composition and contains, in the oil phases O1 and O2 thereof, fine metal oxide particles having ultraviolet screening ability; and a preparation process of the cosmetic composition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090263434 - Powder composed of inorganic compound-loaded polyamide porous particle: Powder composed of fine inorganic compound particles-deposited porous polyamide particles in which the inorganic compound particles are deposited on surfaces and in pores of the porous polyamide particles, the porous polyamide particle have a mean primary particle diameter in the range of 1 to 30 μm, the fine inorganic compound... Agent: Nixon Peabody, LLP

20090263436 - Material primarily for medical, long-term in vivo use, and method for the production thereof: The invention relates to a material that is used primarily for medical, long-term in vivo purposes, e.g. as a filling material in dentistry. The aim of the invention is to create a material primarily for medical, long-term in vivo use which does not have the disadvantages of materials used in... Agent: Jordan And Hamburg LLP

20090263437 - Pesticide compositions: The present invention provides a granular pesticide composition which is highly effective in controlling pests. In particular, the pesticide composition of the present invention is prepared by adsorbing an oil in water emulsion on inert granular particles. These compositions provide improved release of the pesticide. Methods of preparing the granular... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090263438 - Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives: Disclosure is provided for imidazole-triazole derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same.... Agent: Myers Bigel Sibley & Sajovec

20090263439 - Antimicrobial preservative free wipe: A mild and gentle antimicrobial active wet wipe comprising a substrate and a lotion with a pH that ranges from 2.5 to 5.4 and contains no chemical preservatives.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090263440 - Disposable containers and utensils for sanitizing: A disposable container and/or utensil including an uncoated portion and a coated portion. The coated portion includes antibacterial agents and covers a substantially larger external surface area of the disposable container than the uncoated portion. The coated container includes, but is not limited to, a cup, a cup sleeve, or... Agent: Yvette Kendall

20090263441 - Drug depots having diffreent release profiles for reducing, preventing or treating pain and inflammation: Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat inflammation and pain.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263444 - Fluocinolone formulations in a biodegradable polymer carrier: Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263445 - Medical devices comprising spray dried microparticles: An implantable or insertable medical device which includes (a) a tacky polymeric region and (b) spray dried microparticles, which are adhered to the tacky polymeric region. The present invention is further directed to methods of forming such medical devices, and methods of releasing a therapeutic agent within a patient using... Agent: Mayer & Williams PC

20090263443 - Methods for treating post-operative effects such as spasticity and shivering with clondine: Effective treatments of spasticity and shivering that accompanies surgeries are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relax muscle fibers. This administration of clonidine or a pharmaceutically acceptable salt thereof is particularly useful following the surgery.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263442 - Post biopsy cavity treatment implants and methods: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second... Agent: Young Law Firm, P.C. Alan W. Young

20090263450 - Alpha adrenergic receptor agonists for treatment of inflammatory diseases: Effective treatments of pain and/or inflammation from tendonitis, carpal tunnel syndrome, tarsal tunnel syndrome, osteoarthritis, bursitis and/or an oral-facial disease are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263451 - Anti-inflammatory and/or analgesic agents for treatment of myofascial pain: Effective treatments of myofascial pain and/or inflammation are provided. Through the administration of an effective amount of at least one anti-inflammatory agent and/or analgesic at or near a target site, one can reduce, prevent or treat myofascial pain and/or inflammation.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263448 - Clonidine formulation in a polyorthoester carrier: Effective treatments of acute pain for extended periods of time are provided. The treatments include the administration of one or more drug depots at or near a target site wherein the drug depots include an effective amount of clonidine formulated within a polyorthoester. By administration of one or more drug... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263447 - Crosslinked hyaluronic acid and process for the preparation thereof: f

20090263449 - Delivery of nucleic acid complexes from materials including negatively charged groups: Embodiments of the invention include devices and methods for the controlled elution of nucleic acid delivery complexes. In an embodiment, the invention includes a medical device including a substrate surface, a polymeric coating disposed on the surface, the polymeric coating coupled to the substrate surface through the reaction product of... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20090263452 - Drug-eluting intravascular prostheses and methods of use: The present invention provides intravascular prostheses and methods of production and use. An implantable device for treating a vascular disease or disorder includes an intravascular prosthesis containing an inhibitor of smooth muscle cell proliferation and a growth factor. The device can be coated with a biodegradable drug-eluting polymer that is... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090263446 - Method of making load bearing hydrogel implants: Implantable biomaterials, particularly hydrogel substrates with porous surfaces, and methods for enhancing the compatibility of biomaterials with living tissue, and for causing physical attachment between biomaterials and living tissues are provided. Also provided are implants suitable for load-bearing surfaces in hard tissue repair, replacement, or augmentation, and to methods of... Agent: Knobbe Martens Olson & Bear LLP

20090263454 - Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation: Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist and at least one beta adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263453 - Methods and compositions for treating pain comprising a statin: Methods and compositions are provided for reducing, treating or preventing pain and/or inflammation in a patient in need of such treatment, the methods and compositions comprising administering a therapeutically effective amount of a statin or pharmaceutically acceptable salt thereof to a target tissue site beneath the skin.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263461 - Alpha adrenergic receptor agonists for treatment of degenerative disc disease: Effective treatments of pain and/or inflammation from degenerative disc disease and/or facet joint are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a degenerative disc and/or facet joint, one can reduce, prevent or treat pain and/or inflammation caused by the... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263463 - Alpha adrenergic receptor agonists for treatment of pain and/or inflammation: Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263465 - Biopolymer-bioengineered cell sheet construct: A biopolymer-bioengineered human corneal endothelial cell (HCEC) sheet construct for reconstructing corneal endothelium in a patient is recited. The construct includes a biopolymer carrier which is bioresorable and deformable; and a bioengineered cell sheet containing a monolayer of interconnected HCECs with substantially uniform orientation. The bioengineered cell sheet is attached... Agent: Bacon & Thomas, PLLC

20090263464 - Bladder reconstruction: The invention is directed to methods and devices for the reconstruction, repair, augmentation or replacement of laminarily organized luminal organs or tissue structures in a patient in need of such treatment. The device comprises a biocompatible synthetic or natural polymeric matrix shaped to conform to at least a part of... Agent: David S. Resnick

20090263457 - Block copolymer comprising at least one polyester block and a poly(ethylene glycol) block: The present invention provides a block copolymer for a coating on an implantable device for controlling release of drug and methods of making and using the same.... Agent: Squire, Sanders & Dempsey LLP

20090263455 - Dexamethasone formulations in a bioegradable material: Effective treatments of acute pain for extended periods of time are provided. Through the administration of an effective amount of dexamethasone at or near a target site, one can relieve pain cause by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263458 - Material for surgical use in traumatology: The present invention relates to a material, structure, and method for surgical use in traumatology. More particularly, the present invention relates to a composite material, a temporary biocompatible support structure, and related methods of use of the same in aiding osteosynthesis during healing of a bone fracture. The material keeps... Agent: Duane Morris LLP - PhiladelphiaIPDepartment

20090263460 - Medical devices and methods including polymers having biologically active agents therein: The implant design is a drug loaded polymer device, such as a rod, designed to control the release of a biologically active agent, such as clonidine or its derivatives, such as clonidine HCl for a prolonged period of time, such as 2 months, 3 months, 4 months, and even 4.5... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263456 - Methods and compositions for reducing preventing and treating adhesives: Methods and compositions are provided for reducing, treating or preventing adhesions in a patient in need of such treatment, the methods and compositions comprising administering one or more biodegradable drug depots comprising a therapeutically effective amount of a glucocorticoid or pharmaceutically acceptable salt thereof to a target tissue site beneath... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263459 - Methods and compositions for treating intervertebral disc herniations: Methods and compositions are provided for treating an intervertebral disc herniation by local administration of one or more biodegradable drug depots comprising a therapeutically effective amount of a glucocorticoid at or near the intervertebral disc herniation to reduce the size of the intervertebral disc herniation.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263462 - Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine: Effective treatments of dystonia and/or post-stroke spasticity for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve dystonia and/or post-stroke spasticity caused by diverse sources. When appropriate formulations are provided within biodegradable polymers, this relief... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263466 - Herbal composition for treatment of hyperlipidemia and the inhibition of myocardial infarction: A pharmaceutical or medicinal herbal composition and method of making the composition comprised of a mixture of the following herbal ingredients: Glycine max, Plumbago zeylanica, Terminalia arjuna, Trigonella-foenum-graceum, Coleus forskohlii, Commiphora mukul, Camellia sinensis, and Azadirachta indica.... Agent: Volpe And Koenig, P.C.

20090263467 - Combination drug therapy using orally dissolving film or orally disintegrating tablet dosage forms to treat dry mouth ailments: A combination drug therapy can be administered to patients to treat xerostomia or dry mouth or Sjogren's syndrome in the form of orally dissolving film or orally disintegrating tablets. Some of the drugs could be synthetic origin and some drugs are obtained from natural sources.... Agent: Hemant N. Joshi/tara Enterprises

20090263468 - Methods and compositions for wound healing: The present invention relates to methods and compositions for wound healing. In particular, the present invention relates to promoting and enhancing wound healing by utilizing cross-linker covalent modification molecules to attach and deliver wound active agents to a wound. In addition, the present invention provides methods and compositions utilizing oppositely... Agent: Casimir Jones, S.c.

20090263469 - Biguanide-containing liposomes: The present invention relates to biguanide-containing liposomes and antiseptic preparations based on biguanide-containing liposomes, where the liposomes are characterised in that they are essentially free of lipids with anionic head groups, to the preparation of biguanide-containing liposomes and of the antiseptic preparations, and to their possible uses and to the... Agent: Panitch Schwarze Belisario & Nadel LLP

20090263471 - Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof: Herein is described a controlled release pharmaceutical composition of venlafaxine hydrochloride, an effective antidepressant, comprising an inert core; on which the active principle is uniformly layered, that in turn is coated with a layer comprising a hardening agent and a lipophilic agent; the process for the preparation of said pharmaceutical... Agent: Stetina Brunda Garred & Brucker

20090263472 - Endothelin receptor antagonist derivatives: r

20090263474 - Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays: The invention provides a method for treating an autoimmune disease in a subject by administering an interferon antagonist and a Flt3 ligand (Flt3L) antagonist. The invention also provides compositions containing one or more interferon antagonists, and one or more Flt3L antagonists, an in vitro assay for determining a subject's risk... Agent: Brinks, Hofer, Gilson & Lione

20090263473 - Nanoliposome using esterified lecithin and method for preparing the same, and composition for preventing or treating skin diseases comprising the same: The present invention relates to a nanoliposome comprising a liposome membrane containing esterified lecithin, and one or more physiologically active ingredients included in inner space of the liposome membrane; a method for preparing the same; and a composition for preventing or treating skin diseases, comprising the same. The nanoliposome according... Agent: Swanson & Bratschun, L.L.C.

20090263470 - Vaccine compositions comprising virosomes and a saponin adjuvant: This invention provides virosome preparations from an enveloped virus, in particular from influenza virus, containing from said virus, and a saponin adjuvant. In particular the invention provides a virosome preparation from influenza virus an influenza antigen a QS21, optionally with a sterol. The invention also provides vaccine compositions containing said... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090263475 - Dexlansoprazole compositions: Premixes of dexlansoprazole with pharmaceutical excipients, processes for preparing premixes, pharmaceutical formulations containing the premixes, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.... Agent: Dr. Reddy''s Laboratories, Inc.

20090263476 - Composition of rapid disintegrating direct compression buccal tablet: A composition of a rapidly disintegrating buccal dosage form containing a drug, at least one non-effervescent base such as an alkali metal or alkaline earth metal oxide or hydroxide, and a disintegrant. The base regulates the pH gradient to deliver the drug to the buccal, sublingual or oral mucosal membranes... Agent: St. Onge Steward Johnston & Reens, LLC

20090263477 - Salts of fenofibric acid and pharmaceutical formulations thereof: c

20090263478 - Carvedilol forms, compositions, and methods of preparation thereof: Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.... Agent: Cantor Colburn, LLP

20090263479 - Formulations for poorly permeable active pharmaceutical ingredients: The present invention relates to a pharmaceutical oral dosage form containing a poorly permeable active pharmaceutical ingredient and at least one permeability improving substance, wherein the permeability improving substance is thermostably embedded in a water-soluble matrix of a water soluble carrier, and to thermostable formulations which can be used to... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090263480 - Taste-masked pharmaceutical compositions prepared by coacervation: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090263481 - Levetiracetam formulations: Pharmaceutical formulations comprising levetiracetam and having an inner solid phase and outer continuous phase, wherein one or both of the phases comprise at least one hydrophobic material, lipophilic material, or combination thereof.... Agent: Dr. Reddy''s Laboratories, Inc.

20090263482 - Treatment of inflammatory bowel disease with 6-mercaptopurine: Methods of administering a delayed release 6-mercaptopurine pharmaceutical composition to patients suffering from inflammatory bowel disease which provide for release of the 6-mercaptopurine after passage of the pharmaceutical composition through the stomach are disclosed. The methods result in significant clinical improvement despite leading to very little systemic absorption of 6-mercaptopurine... Agent: Kenyon & Kenyon LLP

20090263483 - Nanoparticle formulations and uses thereof: The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages.... Agent: Morrison & Foerster LLP

20090263484 - Tissue engineering devices and methods for luminal organs: Tissue engineering devices and methods are provided for the reconstruction, repair, augmentation, or replacement of a luminal organ or tissue structure involving the use of a biodegradable polymer matrix conforming to a portion of a laminarly arranged luminal organ, the processing of autologous, allogeneic or xenogeneic tissue comprising multiple cell... Agent: Philip S. Johnson Johnson & Johnson

20090263487 - Bubble drink provided by bubbling engineering progress: A bubble drink as a health food, which is produced by imparting a catalytic function for gas escaping to an adsorptive fine food powder to allow the fine food powder to be dispersed in a colloidal solution reverse vessel, and reacting the dispersion with a gas-saturated solution to generate foam... Agent: The Nath Law Group

20090263486 - Nanoparticle-stabilized capsule formulation for treatment of inflammation: A formulation for the delivery of an anti-inflammatory agent to a subject is described. In one particular application of the invention, the formulation comprises oil-based or aqueous droplets comprising indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1-H-indole-3-acetic acid) or celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl) pyrazol-1-yl] benzenesulfonamide) stabilised by nanoparticles, particularly silica nanoparticles.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090263488 - Pressurised metered dose inhalers containing solutions of beta-2 agonists: The present invention relates to a pharmaceutical formulation for use in the administration of 2(1H)-quinolinone derivatives long-acting β2-agonists by inhalation. In particular this invention relates to a chemically stable highly efficient TA 2005 HFA solution formulation to be administered by pressurised metered dose inhalers (pMDIs) characterized by a deep lung... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090263485 - Targeted hollow gold nanostructures and methods of use: Provided are novel nanostructures comprising hollow nanospheres and nanotubes for use as chemical sensors and molecular specific photothermal coupling agents. The nanostructures can be used in laser-induced phototherapy for treatment of cancer and other disorders. The nanostructures can also be used as a sensor that detects molecules. The nanostructures are... Agent: Bell & Associates

20090263489 - Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation: Effective treatments of acute pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulfasalazine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263490 - Microsphere beeswax for mammalian dietary fat mitigation: A device composed of a plurality of beeswax microspheres are contained within a digestible capsule intended for the alimentary tract of the mammal. A method in which the device is ingested orally into the digestive system. A method in which digestive enzymes remove the outside capsule and beeswax microspheres are... Agent: Allan Y. Wu

20090263491 - Polylactide nanoparticles: A drug targeting system for administering a pharmacologically active substance to the central nervous system of a mammal across the animal's blood brain barrier. The drug targeting system comprises nanoparticles made of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide), a pharmacologically active substance which is absorbed to, adsorbed to, and/or incorporated into the nanoparticles,... Agent: D. Peter Hochberg Co. L.p.a.

20090263492 - Diagnostic methods and genetic markers for alzheimer disease: Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy... Agent: Jones Day

20090263493 - Method for making synthetic slug slime and medical use of synthetic and or actual slug slime: The device hereof is most preferably the use of the slime coating of slugs or a synthetic copy of the slug slime, healing agents such as steroids antibiotics, growth hormones or pain killers can be mixed is with the slime before application to a burned or infected area. The slime... Agent: George W. Dishong Esq. Dishong Law Office

20090263494 - Manzanita: Applying the bark of the mariposa Manzanita shrub either mixed into a hot tea or added to mayonnaise and zinc for open sores will cure the herpes virus.... Agent: Robert Emerson

20090263495 - Bacteriostatic or bacteriocidal compositions and methods: Particular aspects provide compositions and methods for treating or preventing bacterial infection or at least one symptom related to bacterial infection, and the like in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein,... Agent: Davis Wright Tremaine, LLP/seattle

20090263496 - Method for producing metal particles, metal particles produced thereby, and the use thereof: r

20090263497 - Production method for calcium phosphate nano-particles with high purity and their use: The present invention provides a continuous process for producing calcium phosphate nanoparticles in a network mixer or static mixer reactor, fed by a calcium solution, a phosphorous solution and an alkaline solution and, optionally, one solvent or dispersing agent. The proposed process enables the micromixing control, which is essential to... Agent: Sughrue Mion, PLLC

20090263498 - Pharmaceutical preparations for treating inflammatory diseases: e

20090263501 - Activated oxidizing vapor treatment system and method: An oxidizing liquid (20), such as hydrogen peroxide, is vaporized (18) and the vapor is used to deactivate nerve gas, blistering gas, or other biologically active substances such as pathogens, biotoxins, and prions. A second chemical compound (42) in vapor, mist, or fog form is used in conjunction with the... Agent: Fay Sharpe LLP

20090263499 - Area decontamination via low-level concentration of germicidal agent: Provided is a method of decontaminating an area, and related device. The method comprises releasing a germicidal agent into the area from a germicidal source, controlling the germicidal agent concentration in the area to a predetermined concentration that does not exceed a Permissible Exposure Limit, and contacting microorganisms in the... Agent: K&l Gates LLP

20090263500 - Composition and method for treating bedsores, cuts and burns: The invention provides a composition and method to prevent and treat bedsores rapidly, efficaciously and economically. The composition comprises a novel combination of herbal extracts that has surprisingly synergistic and highly efficacious effects for the acceleration of wound healing, and which also disinfects and relieves pain in dermal wounds. The... Agent: F. Russell Denton, Ph.d., Esq.

20090263502 - Highly dispersible titanium dioxide powder: Provided is a means for controlling a plant disease or a pest insect by utilizing a highly dispersible titanium dioxide powder produced by a discharge treatment of a titanium dioxide powder. Titanium dioxide is a substance which is highly safe to living organisms and the environment. A plant disease or... Agent: Birch Stewart Kolasch & Birch

20090263503 - Compositions for cleaning contained bodies of water with metal hydrates: Compositions for cleaning, sanitizing and maintaining contained bodies of water such as swimming pools, wading pools, fountains, ornamental ponds, etc. The compositions include pre-determined percentages of hydrates of copper sulfate, zinc sulfate, and aluminum sulfate by weight. The composition uses hydrates of copper, zinc and aluminum sulfates instead of the... Agent: Lesavich High-tech Law Group, P.C.

20090263504 - Methods and compositions for promoting activity of anti-cancer therapies: The present invention relates to a method of inhibiting growth of a cancerous cell. The method includes the step of exposing the cancerous cell to an anti-cancer therapy and an effective amount of a steroid saponin.... Agent: Klarquist Sparkman, LLP

20090263505 - Dietary therapeutic compositions for ameliorating disease symptoms and conditions associated with diabetes: A daily dietary supplement for improving glucose metabolism, said dietary supplement comprising: an effective amount of a source of Alpha Lipoic Acid; an effective amount of a source of Salacia Oblonga; an effective amount of a source of Gymnema Sylvestre; an effective amount of a source of Chromium; an effective... Agent: Michael Ries

20090263506 - Calcareous organism growth accelerator: The purpose of this invention is to provide compositions useful for promoting the growth of calcareous organisms present in a closed system aquatic habitat. Particularly, to composition capable of efficiently delivering calcium and carbonate to the calcareous organisms. Most particularly, to a composition effective for enhanced delivery of aragonite to... Agent: Mchale & Slavin, P.A.

20090263507 - Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use: The invention provides methods and kits for treatment of pain, inflammation, neuronal or vascular injury and the use of biomarkers for the assessment of the biological activity or disease state. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, a bioactive agent, such as a magnesium... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263508 - micronutrient supplement with calcium, vitamin d or calcium & vitamin d combination for premenstrual syndrome, postpartum depression, depression and panic attacks: A bolus dose supplement, foodstuff, beverage and beverage concentrate with calcium and vitamin D for the treatment and prevention of PMS, panic attacks, and postpartum depression. The combination of adequate calcium and vitamin D is provided as a multi-vitamin and mineral supplement. The bolus dose is comprised of 2 main... Agent: Gottlieb Rackman & Reisman PC

20090263509 - Antibacterial agent and antibacterial composition: The problems to be solved by the invention are to provide antibacterial agents originated from natural products that are safe for regular use with potent antibacterial activity, and antibacterial compositions containing said antibacterial agents. Antibacterial agents containing Eysenhardtia adenostylis extract or isoflavan compounds are a solution to the problem. Also... Agent: Brooks Kushman P.C.

20090263512 - Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof: This invention provides compositions, methods and process of producing extracts from Xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for treating cancer, arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease,... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090263511 - Insecticidal composition: The use of dill oil or a mixture of two or more components thereof as a potentiator for a pesticide, such as an insecticide and in particular a pyrethroid is described, together with compositions containing dill oil, and their use in agriculture and in veterinary applications.... Agent: Intellectual Property / Technology Law

20090263510 - Process of making hoodia plant extract with improved flavor: Processes of making extracts of Hoodia plant containing steroidal glycosides which have improved flavor, by virtue of reduced Levels of discovered negative flavor compounds.... Agent: Unilever Patent Group

20090263513 - Cosmetic skin lightening formulation: The present invention features novel cosmetic skin care compositions for lightening hyperpigmentation.... Agent: Bozicevic, Field & Francis LLP

20090263514 - Cold and flu tonic: A method and composition for reducing the symptoms of the common cold and flu in a human subject in need thereof, comprising the administration of an effective amount of an aqueous composition having all components dispersed as a dry powder concentrate or dissolved in a decoction therein comprising Black pepper,... Agent: Govindan Gopinathan, Md

20090263515 - Pest repellent compositions and methods: The invention is directed to a topical insect repellent with extended duration of protection and that was obtained by combining natural and organic plant essential oil compounds. The new natural repellent exhibits the longevity and repellency that is comparable to or better than N,N-diethyl-m-toluamide (DEET), a synthetic compound employed in... Agent: Nixon & Vanderhye, PC

20090263516 - Plant extract composition and their use to modulate cellular activity: Extracts from plant material, or semi-purified/purified molecules or compounds prepared from the extracts that demonstrate the ability to modulate one or more cellular activities are provided. The extracts are capable of slowing down, inhibiting or preventing cell migration, for example, the migration of endothelial cells or neoplastic cells and thus,... Agent: Sheppard, Mullin, Richter & Hampton LLP

20090263517 - Method for producing margosa extract: The invention relates to a method for producing a margosa extract, an oil from cores and/or seeds of the neem tree being used and the oil being extracted using a carbon dioxide-containing extracting agent. The invention further relates to a margosa extract as is obtained using the method, its use... Agent: Scott R. Cox Lynch, Cox, Gilman & Mahan, P.s.c.

20090263519 - Composition and methods for inducing the expression of heat shock proteins: A nutritional composition comprising at least an effective amount of geranylgeranylacetone or derivative of geranygeranylacetone and/or paeoniflorin or derivative of paeoniflorin and an effective amount of Schisandrin B, wherein the ingredients act substantially simultaneously, via differing mechanism, to enhance the expression of heat shock protein in cells, particularly heat shock... Agent: Iovate Health Science Research Inc.

20090263518 - Composition and uses thereof: A composition for topical application to the skin comprises a cocoa polyphenol extract in combination with an SUS-rich fat, wherein the cocoa polyphenol extract is present in an amount of less than 15% by weight based on the weight of the SUS-rich fat, and a cosmetically acceptable carrier. The composition... Agent: Hoxie & Associates LLC

20090263520 - Nematicidal composition: A nematicidal composition comprising (i) one or more essential oils selected from Tagetes erecta oil, Ocimum basilicium (sweet basil) oil or a Cymbopogon martini (palmerosa) oil, or a mixture thereof, or certain components thereof which have nematicidal effect (ii) an agriculturally acceptable carrier oil and (iii) an emulsifier.... Agent: Townsend And Townsend And Crew, LLP

20090263521 - Composition for the treatment of cancers and inhibition of metastasis containing extracts or fractions of the magnolia obovata: The present invention relates to a composition containing the extracts of Magnolia obovata Thunberg or fractions thereof for the prevention and treatment of cancer and for the inhibition of metastasis. Particularly, the extracts of Magnolia obovata Thunberg fruits and floral buds extracted with water, alcohol or a mixture thereof as... Agent: Lucas & Mercanti, LLP

20090263522 - Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2: A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species or a beta-acid species or... Agent: Mcdermott Will & Emery LLP

20090263523 - Enhancer of cholinesterase activity: The invention provides an enhancer for cholinesterase. An enhancer comprising Gam Arabic as an active ingredient is useful for preventing and/or treating a decreased cholinesterase activity due to liver damage or inhibition of cholinesterase as a side effect of various agents.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090257949 - Radiopharmaceutical imaging of neurodegenerative diseases: Methods for simultaneously detecting dementia or cognitive impairment, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Lewy Body Dementia (LBD) and Vascular Dementia (VaD) in a patient using dual or multiple radiopharmaceutical probes are provided herein.... Agent: Pepper Hamilton LLP

20090257952 - Engineered integrin binding peptides: Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (α5β1) or vitronectin (αvβ3 and αvβ5 integrins) are disclosed. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence... Agent: Peters Verny , L.L.P.

20090257950 - Membrane scaffold proteins: The membrane scaffold proteins (MSP) of the present invention assemble with hydrophobic or partially hydrophobic proteins to form soluble nanoscale particles which preserve native structure and function; they are improved over liposomes and detergent micelles, both in terms of stability and preservation of biological activity and native conformation. In the... Agent: Greenlee Winner And Sullivan P C

20090257951 - Ngr receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same: The present invention provides a method of identifying a tumor homing molecule that homes to angiogenic vasculature by contacting a substantially purified NGR receptor with one or more molecules and determining specific binding of a molecule to the NGR receptor, where the presence of specific binding identifies the molecule as... Agent: Mcdermott, Will & Emery

20090257953 - Novel fluorine-18 labeled rhodamine derivatives for myocardial perfusion imaging with positron emission tomography: The present invention is directed toward novel fluorine-18 labeled rhodamine dye derivatives and methods of making the same. The present invention is also directed toward methods of using novel fluorine-18 labeled rhodamine dye derivatives as positron emission tomography imaging agents and myocardial perfusion imaging agents.... Agent: David S. Resnick

20090257954 - Development of a simple animal model for infection by viruses and other obligate intracellular parasites: The present invention provides methods for studying pathogenesis of mammalian viruses. In particular, the present invention provides a nonhuman animal model system for studying disease mechanisms wherein the nonhuman animal model is infected with an animal virus. In a preferred embodiment the animal model is C. elegans and the animal... Agent: Angela Foster, Phd, Esq.

20090257955 - Sheep model of neuropathic pain behavior and uses thereof: Methods for producing peripheral nerve injury in sheep are provided. The sheep model provides a model of persistent neuropathic pain in humans. Methods for drug delivery are provided. Also provided is a method for screening potentially therapeutic agent for the treatment of persistent neuropathic pain. Also provided are the methods... Agent: Benjamin Aaron Adler Adler & Associates

20090257956 - Treatment method for treatment of erectile dysfunction and premature ejaculation: A method for a same visit treatment for erectile dysfunction and premature ejaculation. The method includes: performing a diagnostic on the patient using physical conditions of the patient; determining a diagnostic group of the patient, wherein each diagnostic group has corresponding conditions to the physical conditions of the patient; identifying... Agent: Baker & Hostetler LLP

20090257957 - Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders: This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for aerosolized delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders... Agent: Wilson, Sonsini, Goodrich & Rosati

20090257958 - Pesticidal compositions: The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations.... Agent: Patent Docket Department Armstrong Teasdale LLP

20090257959 - Pesticidal compositions: The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations.... Agent: Patent Docket Department Armstrong Teasdale LLP

20090257960 - Neutralized acid group-containing polymers and the use thereof: The present invention relates to a polymer component which consists of one polymer or of a plurality of different polymers, comprises at least one polyurethane, where the polymer or at least one of the polymers has acid groups which are neutralized partially with at least one inorganic base and partially... Agent: Connolly Bove Lodge & Hutz LLP

20090257961 - Denture care composition: This invention relates to a new denture care composition and method of use. In particular, this invention relates to a film-forming denture care composition that kills odor causing bacteria, maintains prolonged fresh breath for two or more hours and is an effective guard against denture odor.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090257962 - Compositions for human dental care: Compositions of the invention are water-based formulas that contain natural ingredients which aid in reduction of bacteria in the mouth, thereby reducing plaque and the production of tartar, and in one aspect of the invention are formulated as potable dental water that may be consumed in place of regular consumption... Agent: Morriss Obryant Compagni, P.C.

20090257964 - Fluoride-releasing strips for caries prevention: The present invention discloses fluoride-releasing strips for caries prevention, wherein the fluoride-releasing strips comprises a colloidal fluoride-containing solution for releasing fluorine ion and a support substrate. A colloidal fluoride-containing solution comprises a fluoride solution, at least one buffer, at least one moisturizer and a carboxymethyl cellulose (CMC). The concentration of... Agent: Wpat, PC

20090257963 - Method for measurably improving oral health: A composition for measurably improving oral health, a system including the composition, a method of using the composition and system, and a method of forming the composition and system are disclosed. The composition is a gel that maintains contact with a portion of an oral cavity for an extended period... Agent: Snell & Wilmer L.L.P. (main)

20090257965 - Abnormal protein removing composition: Provide an effective composition for removing abnormal protein. Also, a composition for removing abnormal protein whose main ingredient is soyasaponin B group, which is used to provide a composition, agent or food contributing to the prevention or treatment of diseases caused by proteolysis abnormality, among others.... Agent: Knobbe Martens Olson & Bear LLP

20090257966 - Ternary and quaternary wax-resin composites for use in cosmetic and pharmaceutical preparations: A wax-resin composite is made by melting thermoplastic hydrocarbon resin, optionally with an antioxidant. The melted thermoplastic hydrocarbon resin and waxes are blended at a temperature sufficient to melt the waxes. After blending and melting, the blended thermoplastic hydrocarbon resin and waxes are allowed to solidify. Solidification is followed by... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090257967 - Compositions comprising sugar beet pectin and carotenoids: Carotenoid compositions for use as colorants or additions for food, animal feeds, cosmetics or drugs comprise finely dispersed carotenoids in a sugar beet matrix.... Agent: Stephen M. Haracz, Esq. Bryan Cave LLP

20090257968 - Gels containing anionic surfactants and coupling agents: The present invention provides an enhanced gelling agent composition comprising a mixture of an anionic surfactant and a coupling agent. The invention also describes compositions in gel form comprising: (a) a solvent selected from the group consisting of polar solvents, non-polar solvents and combinations thereof; and (b) a gelling agent... Agent: Isaac A. Angres

20090257969 - Soft anticholinergic zwitterions: e

20090257970 - Antiperspirant compositions containing a copper salt and a penetration enhancer and methods of using the same: Antiperspirant compositions including a copper salt and a penetration enhancer are described. The penetration enhancer may be salicylic acid or urea. In addition to a copper salt, the composition may also comprise an aluminum or zirconium salt. Methods of using the compositions are also described. Embodiments may be useful in... Agent: Lawrence F. Rozsnyai

20090257971 - Antiperspirant composition: An antiperspirant composition with the antiperspirant composting containing a thickening agent in sufficient quantity so as to produce an antiperspirant composition wherein the viscosity is less than 2400 centpoises.... Agent: Jacobson & Johnson

20090257972 - Cosmetic and dermatological compositions in particular for the treatment of keratin containing substrates: The present invention relates to cosmetic and/or dermatological compositions for the treatment of keratin containing substrates, comprising synergistic mixtures of modified starch polymers with defined molecular weights and cationic charges in a cosmetically acceptable medium. The synergistic mixtures of modified starches employed to manufacture compositions according to the present invention... Agent: Roberts & Roberts, LLP Attorneys At Law

20090257973 - Malodor reducing composition, fragrance composition and product comprising the same: wherein R4, R5 and R7 are each independently, a C1-C5 linear or branched alkyl or alkenyl group, R6 is a (C1-C5) alkylidene, R4 and R5 may form a C4-C7 saturated or unsaturated alicyclic or hetrocyclic ring structure which may be mono-substituted or poly-substituted by (C1-C4) alkyl groups, and R6 and... Agent: Sughrue-265550

20090257974 - Perfume compositions: Perfume compositions comprise between 10% and 30% in total by weight of perfume ingredients selected from two groups, Group A, Group B, with the provisos that over 5% but less than 15% of the perfume composition must comprise Group A ingredients, and for compositions comprising less than 10% of Group... Agent: Norris, Mclaughlin & Marcus

20090257975 - Solid and semi-solid polymeric ionic conjugates: Aqueous solubility of drugs including insoluble or poorly soluble drugs such as ziprasidone is improved using a functional polymer to form an ionic conjugate with said drug.... Agent: Pfizer Inc. Patent Department

20090257976 - Single vial formulation for medical grade cyanoacrylate: Alkyl cyanoacrylate compositions and methods for making those compositions, utilizing high purity monomeric starting materials, formed into more viscous oligomers, and combined with a plasticizer and inhibitor to provide a single-container, storage stable medical cyanoacrylate.... Agent: Knobbe Martens Olson & Bear LLP

20090257977 - Novel tetrahydropyridothiophenes: Compounds of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.... Agent: Millen, White, Zelano & Branigan, P.C.

20090257978 - Antiviral coumpounds: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences Inc

20090257980 - Anti-virus therapy for respiratory diseases: The present invention provides the use of IFN-β, an agent that increases the expression of IFN-β, or a polynucleotide which is capable of expressing IFN-β or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive... Agent: Morrison & Foerster LLP

20090257979 - Novel inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in... Agent: Knobbe Martens Olson & Bear LLP

20090257982 - medical device for treating diabetes mellitus, obesity, chronic fatigue, aging, and other medical conditions by utilizing modified virus virions to insert messenger ribonucleic acid molecules into cells: The common link between diabetes mellitus, obesity, chronic fatigue and even aging may be related to deficiencies involving a body's metabolism of glucose and the ability to optimally conduct the necessary biologic processes of aerobic respiration. Utilizing a medical device comprised of a modified form of virus to deliver to... Agent: Lane B. Scheiber

20090257983 - Medical treatment device for treating aids by utilizing modified human immunodeficiency virus virions to insert anti-viral medications into t-helper cells: The medical device by which a modified Human Immunodeficiency Virus or virus-like structure is used as a transport medium to carry a payload of a quantity of anti-viral drug molecules to T-Helper cells in the body. The modified Human Immunodeficiency Virus or virus-like structure makes contact with a T-Helper cell... Agent: Lane B. Scheiber

20090257981 - Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same: Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090257991 - Engineering and delivery of therapeutic compositions of freshly isolated cells: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered... Agent: Fulbright & Jaworski L.L.P.

20090257990 - Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues: Polynucleotide expression constructs, populations of cells and methods of treating diseases caused by dysfunction in, or damage to, excitable tissues are provided.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090257992 - Adjunctive agent for lavaging the alimentary canal comprising butyric acid bacterium and/or lactic acid bacterium: The present invention provides an adjunctive agent for lavaging the alimentary canal which is able to reduce a dose of oral cleaning agent for lavaging the alimentary canal, and is capable of realizing an excellent cleaning effect at the time of use of the aforementioned oral cleaning agent for lavaging... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090257993 - Lactic acid producing bacteria and lung function: The present invention provides novel use for live (probiotic) lactic acid producing bacteria, dead or non-viable bacteria thereof, as well as food supplements, nutritive compositions and/or pharmaceutical compositions comprising these, for the treatment or prophylaxis of lung dysfunction in a subject. A suitable lactic acid producing bacterium has a significant... Agent: Jay S Cinamon Abelman, Frayne And Schwab

20090257995 - Harmful bacterium control agent containing bacillus thuringiensis: Through inhibition of the multiplication of pathogenic bacteria and inactivation of bacterial self-induced factors, the balance of intestinal flora is improved to thereby promote regulation of animal intestinal functions and enable prevention/treatment of infection disease caused by such pathogenic bacteria. Accordingly, a pharmaceutical containing Bacillus thuringiensis is administered to animals,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090257984 - Antifungal compositions containing the endophyte fungus alternaria alternata and or its metabolites, as antagonist agents of plasmopara viticola: The present invention relates to compositions containing the fungus Alternaria alternata and/or the secondary metabolites thereof, which belong to the family of the diketopiperazines (DKPs), for controlling the pathogen fungus Plasmopara viticola.... Agent: Nixon & Vanderhye, PC

20090257986 - Epidermal and dermal equivalents: The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood... Agent: Fulbright & Jaworski L.L.P.

20090257989 - Intraperitoneal delivery of genetically engineered mesenchymal stem cells: A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia,... Agent: Mcandrews Held & Malloy, Ltd

20090257987 - Method of generating dopamine-secreting cells: Methods of generating cells which secrete dopamine are disclosed. One method comprises incubating mesenchymal stem cells in a culture medium comprising brain derived neurotrophic factor (BDNF), wherein the culture medium comprises no more than 0.1 μM retinoic acid (RA). Another method comprises incubating mesenchymal stem cells in a culture medium... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090257988 - Methods and compositions for accelerating the generation of regulatory t cells ex vivo: The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation... Agent: Morgan, Lewis & Bockius, LLP

20090257985 - Methods of regulating expression of genes or of gene products using substituted tetracycline compounds: The present invention relates, at least in part, to the use of substituted tetracycline compounds for regulation of expression of nucleic acids operably linked to a tetracycline operator system. The invention pertains to compounds used in a regulatory system which utilizes components of the Tet repressor/operator/inducer system of prokaryotes to... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090257994 - Chimeric immunoreceptor useful in treating human cancers: The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090257996 - Dietary supplement energy-providing to skeletal muscles and protecting the cardio vascular tract: Dietary supplements—providing energy and strengthening skeletal muscles and facilitating skeletal muscles ability to sustain prolonged periods of physical activity—containing propionyl-L-carnitine or one of its salts, coenzyme Q10, nicotinamide, riboflavin, pantothenic acid and optionally other components such as amino acids and creatines.... Agent: Lucas & Mercanti, LLP

20090257997 - Stable aqueous compositions comprising bioactive creatine species: Compositions containing one or more bioactive forms of creatine which are aqueous compositions in which the one or more bioactive forms of creatine do not appreciably degrade into creatinine. Also are methods for providing various beneficial effects which comprise administering aqueous compositions comprising at least one creating O-phosphate species to... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090257998 - Method for treating heart attacks, strokes and diabetic crisis by utilizing modified virus virions to insert necessary protein molecules and vital nutrients into targeted cells: The common link between incurring a heart attack, suffering a stroke or diabetic crisis is related to deficiencies involving a body's metabolism of glucose and the ability to optimally conduct the necessary biologic processes of aerobic respiration to produce energy molecules. Utilizing a medical treatment method comprised of a modified... Agent: Lane B. Scheiber

20090257999 - Method of preventing contrast-induced nephropathy: The present invention relates to methods of preventing contrast-induced nephropathy including the step of administering an effective amount of a compound (e.g., a peroxynitrite decomposition agent, a PARP inhibitor or a superoxide dismutase mimic) to a subject to be administered a contrast agent.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090258000 - Mucosally non-irritative amphotericin b formulations and methods for treating non-invasive fungus-induced mucositis: The present invention is directed to compositions and methods for non-irritatively treating and preventing non-invasive fungus-induced mucositis. Specifically, the invention involves compositions including a mucosally non-irritative mixture of amphotericin B and a pharmaceutically acceptable carrier. Such compositions can be non-irritatively mucoadministered to prevent, reduce, or eliminate chronic non-invasive fungus-induced mucositis... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090258001 - Administration of anti-cd3 antibodies in the treatment of autoimmune diseases: A method of treating an autoimmune disease, such as, diabetes or psoriasis, by administering an anti-CD3 antibody, or anti-CD3 antibody fragment. The anti-CD3 antibody, or antibody fragment, is administered over a course of treatment wherein, during the course of treatment, the anti-CD3 antibody, or anti-CD3 antibody fragment is administered in... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20090258002 - Biomarkers for tissue status: The invention relates to methods of accurately and quickly diagnosing and monitoring the progression of cancer and ischemally injured tissue. The invention also provides methods of treatment as well as methods of screening for compositions useful for treating the disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20090258003 - Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular VT and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for... Agent: Celera Corporation

20090258004 - Human blood proteins expressed in monocot seeds: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.... Agent: Arent Fox LLP

20090258006 - Method of modulating neovascularization: The invention provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in an amount effective to inhibit neovascularization. The invention also provides a method of identifying an agent that inhibits neovascularization. The method comprises... Agent: Marshall, Gerstein & Borun LLP

20090258005 - Therapeutic compositions and methods: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.... Agent: Ropes & Gray LLP

20090258007 - Anti-perp antibody: The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is useful for treatment of various diseases which highly expresses... Agent: Sughrue Mion, PLLC

20090258011 - Antibodies against west nile virus and therapeutic and prophylactic uses thereof: The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions.... Agent: Drinker Biddle & Reath (dc)

20090258014 - Combination of hgf inhibitor and egf inhibitor to treat cancer: The present invention is directed toward a method of treating cancer by administering to a patient an inhibitor of Hepatocyte Growth Factor and an inhibitor of, e.g., Epidermal Growth Factor.... Agent: Townsend And Townsend And Crew, LLP

20090258012 - Compositions and methods for treating inflammatory disorders: The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20090258010 - Methods, compositions, and kits for treating shiga toxin associated conditions: The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (cαStx1) and anti-Shiga Toxin 2 (cαStx2) antibodies.... Agent: Clark & Elbing LLP

20090258015 - Modulators of candida hyphal morphogenesis and uses thereof: The invention relates to modulation of fungal morphology between yeast-to-hyphal growth transition by controlling muramyl-L-alanine concentration and uses thereof.... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20090258013 - Novel compositions and methods for the treatment of immune related diseases: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Genentech, Inc.

20090258009 - Protofibril selective antibodies and the use thereof: The present invention pertains to the prevention, treatment and diagnosis of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More specifically to high affinity antibodies selective for amyloid beta protein (Aβ) in its protofibril conformation and of IgG class and IgG1 or IgG4 subclass or combinations thereof or... Agent: Clark & Elbing LLP

20090258016 - Substituted imidazole derivatives: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:... Agent: Novartis Institutes For Biomedical Research, Inc.

20090258008 - Uses of the fcrn receptor: The invention relates to the field of biochemistry and molecular biology. More specifically the invention relates to the production of (monoclonal) antibodies and even more specifically to the production of therapeutic and diagnostic antibodies. The invention provides a method for producing an antibody or a functional part, derivative and/or analogue... Agent: Traskbritt, P.C.

20090258017 - Lyophilized therapeutic peptibody formulations: The present invention provides long-term stable formulations of a lyophilized therapeutic peptibody and methods for making a lyophilized composition comprising a therapeutic peptibody.... Agent: Amgen Inc.

20090258018 - Methods for treating juvenile idiopathic arthritis: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for... Agent: Lahive & Cockfield, LLP/abbott Floor 30, Suite 3000

20090258019 - Diagnosis of carcinoma using raig1 polypeptides: The present invention relates to the new uses of a polypeptide (retinoic acid-inducible gene 1; RAIG1, also known as hypothetical protein FLJ10899 or retinoic acid induced 3) compositions comprising the polypeptide, including vaccines, antibodies that are immunospecific for the polypeptide and agents which interact with or modulate the expression or... Agent: Klauber & Jackson

20090258020 - Antibody designated barb3, barb3 related antibodies, and methods of making and using same: The invention provides antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment and diagnostic methods. One treatment method includes inhibiting growth or proliferation of proliferating cells, such as hyperproliferative cells or... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090258022 - Antibodies to brain specific membrane protein: A novel gene apparently encoding a transmembrane glycoprotein has been successfully isolated by constructing a cDNA library of 4 kb or above in size from mRNA expressed in human adult brain and analyzing the structures of the cDNAs contained within said library by the shotgun method. The novel gene shows... Agent: Fish & Richardson PC

20090258021 - Genes associated with mechanical stress, expression products therefrom, and uses thereof: The disclosure relates to human and mechanical stress induced genes, in particular gene 608, and functional equivalents, probes therefor, tests to identify such genes, polypeptide expression products of such genes, antibodies to the polypeptides, uses for such genes, expression products and antibodies, e.g., in diagnosis (for instance risk determination), treatment,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090258023 - Tgf-beta superfamily binding proteins and modulation of bone formation and loss: The present invention relates to novel polynucleotides and polypeptides that are expressed in osteoblasts, interact with members of the TGF-β superfamily, and inhibit mineralization. The invention further relates to the use of these polynucleotides and polypeptides to modulate bone formation and bone loss.... Agent: Myers Bigel Sibley & Sajovec

20090258024 - Compositions and methods for diagnosis and treatment of chronic inflammatory diseases: This invention relates to methods and compositions for diagnosis and treatment of chronic inflammatory diseases by blocking CD147 interaction with extracellular cyclophilin. Specifically, the methods and compositions of this invention regulate recruitment of leukocyte to the infection site by specifically blocking the CD147 domain involved with the chemotactic function without... Agent: Law Offices Of Khalilian Sira, LLC

20090258025 - Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders: Methods for the treatment of cancer with therapies targeting tumor-associated macrophage activities are provided. Methods for the treatment of cancer, inflammatory and autoimmune disorders with therapies using tumor-associated macrophages and adipose tissue macrophages are also provided.... Agent: Genentech, Inc.

20090258026 - Anti-notch1 nrr antibodies and methods using same: The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.... Agent: Clark & Elbing LLP

20090258027 - Methods of modulating immune function: The invention relates to methods for modulating the immune function through targeting of CLIP molecules as well as gamma delta T cells. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease,... Agent: Wolf Greenfield & Sacks, P.C.

20090258028 - Methods of forming coatings for implantable medical devices for controlled release of a peptide and a hydrophobic drug: This invention is generally related to methods of forming coatings for implantable medical devices, such as drug delivery vascular stents. The methods are for forming coatings to control the release of a peptide such as RGD, and a hydrophobic drug. Both single layer and multiple layer coating constructs are encompassed... Agent: Squire, Sanders & Dempsey LLP

20090258029 - Heparin prodrugs and drug delivery stents formed therefrom: A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a... Agent: Squire, Sanders & Dempsey LLP

20090258030 - Materials and methods for improving livestock productivity: The subject invention provides methods for improving livestock health. In specific embodiments, the invention provides methods for accelerating and/or augmenting livestock growth; improving immunity; and enhancing fertility in livestock. To do so, the present invention provides materials and methods for administering a cysteamine compound to livestock.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090258031 - Immunosuppressive polypeptides and nucleic acids: The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.... Agent: Maxygen, Inc. Intellectual Property Department

20090258032 - Methods and compositions targeting viral and cellular itam motifs, and use of same in identifying compounds with therapeutic activity: This invention provides methods of treating, reducing the incidence of, and inhibiting metastasis formation of carcinomas, sarcomas, Epstein-Barr virus-induced malignancies, B cell proliferative disorders, and mast cell activation disorders, comprising administering to a subject a compound that inhibits an interaction of a first protein and an immunoreceptor tyrosine-based activation motif... Agent: Pearl Cohen Zedek Latzer, LLP

20090258033 - Hcv e1e2 vaccine compositions: HCV E1E2 compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or immunostimulatory nucleic acid sequences are described. The compositions can be used in methods of stimulating an immune response in a vertebrate subject.... Agent: Novartis Vaccines And Diagnostics Inc.

20090258034 - Method of inducing mucosal immune response to antigen with dioscorea polysaccharides adjuvant: A method for inducing mucosal immune responses in a subject in need thereof to an antigen includes administering to the subject a vaccine composition including the antigen and a Dioscorea polysaccharides as an adjuvant. Because of the immuomodulatory effect of the Dioscorea polysaccharides, the vaccine composition is further capable of... Agent: Panitch Schwarze Belisario & Nadel LLP

20090258035 - Avian virus vaccines and uses thereof: The present invention relates to poultry vaccines for prevention of Newcastle disease.... Agent: Usda-ars-office Of Technology Transfer Patent Advisors Office

20090258036 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3' -utr of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090258037 - Vaccine development strategy using microgravity conditions: Methods are provided herein for producing a vaccine, comprising culturing bacteria in microgravity. In some examples, the method includes culturing bacteria in microgravity, evaluating RNA expression, detecting an RNA that is over- or underexpressed during culture in microgravity, deleting the over- or underexpressed RNA in bacteria, and killing or attenuating... Agent: Klarquist Sparkman, LLP

20090258039 - Method of administering a pharmaceutical active ingredient: A method for reducing the friability of soft substrates by applying an effective amount of a water soluble, polymeric dispersion to at least a portion of a treatment surface of the substrate, such that less than about 90% of the exterior surface has the dispersion applied thereto.... Agent: Philip S. Johnson Johnson & Johnson

20090258040 - Steroid treatment for hot flashes: Embodiments of the invention relate to methods for treating individuals suffering from hot flashes by vomeronasally administering a therapeutically effective dosage of a steroid agent. The hot flashes may be a result of postmenopause or castration suffered by the individual. In many embodiments, the method for treating individuals suffering with... Agent: Patterson & Sheridan, L.L.P.

20090258038 - Water-soluble compositions of bioactive lipophilic compounds: wherein: X is a residue of a hydrophobic moiety, Y is a residue of a hydrophilic moiety, p is 1 or 2, m is 0 or 1, and n is an integer greater than or equal to 0 are disclosed. The lipophilic compound is preferably selected from the group consisting... Agent: Morgan, Lewis & Bockius LLP (sf)

20090258043 - Dispersions comprising acylglutamates: The invention relates to dispersions comprising water, lipophilic phase and emulsifier, characterized in that the emulsifier is present in an amount of less than or equal to 3% by weight based on the total weight of the dispersion, and in that the emulsifier comprises at least one acylglutamate. The dispersions... Agent: Fox Rothschild LLP

20090258042 - Encapsulated active materials containing adjunct crosslinkers: It is an object of the present invention to provide a microcapsule product comprising an active material; said active material encapsulated by a polymeric material to provide a polymer encapsulated material wherein said polymeric material comprises an adjunct crosslinker.... Agent: International Flavors & Fragrances Inc.

20090258041 - Protection of oxidizable agents: Formulations for cosmetical or pharmaceutical use contain an antioxidant in encapsulated form and a cosmetically or pharmaceutically acceptable carrier. The antioxidant is selected from carbon bridged hindered phenoles, ester bridged hindered phenoles, amide bridged hindered phenoles, lactones of hindered phenoles, sterically hindered oxylamines and sterically hindered hydroxylamines. The encapsulated antioxidant... Agent: Joann Villamizar Ciba Corporation/patent Department

20090258044 - Kit for insect bites: A travel kit used for inhibiting and reducing the incidence and effect of insect bites. The kit includes a pouch for enclosing a plurality of containers therein. The pouch has a closure means to maintain the containers in the pouch and a means for removably attaching the pouch to a... Agent: Michael E. Zall

20090258045 - Structures including antimicrobial peptides: A structure includes a substrate and a first plurality of bilayers on the substrate. The first plurality of bilayers includes a first layer including an antimicrobial peptide having a charge, and a second layer including a polyelectrolyte having a charge opposite the charge of the first layer. At least a... Agent: Choate, Hall & Stewart LLP

20090258046 - Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent: A pharmaceutical or veterinary composition, which comprises a first active agent selected from a non-glucocorticoid steroid or analogues, a ubiquinone, or salts thereof, and a second active agent comprising a bronchodilator. The composition is provided in various formulations and in the form of a kit. The products of this patent... Agent: Wilson, Sonsini, Goodrich & Rosati

20090258047 - Heparin prodrugs and drug delivery stents formed therefrom: A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a... Agent: Squire, Sanders & Dempsey LLP

20090258052 - Compounds and methods for altering bone growth: p

20090258050 - Controlled drug delivery using a zein layer modified with levulinic acid: The disclosure relates to medical devices coated with zein admixed with levulinic acid. The medical device may further include a therapeutic agent in contact with zein admixed with levulinic acid. Zein admixed with levulinic acid allows the therapeutic agent to be retained on the device during delivery and also controls... Agent: Brinks Hofer Gilson & Lione/chicago/cook

20090258049 - Drug eluting expandable devices: The present disclosure relates to drug eluting devices, and their uses. The drug eluting devices can allow for perfusion during deployment. The coatings the may contain bioactive materials which elute once deployed in a patient and can have anti-proliferative, anti-inflammation, or anti-thrombotic effects. Sol gel technology can be used to... Agent: K&l Gates LLP Attn: Michelle S. Glasky, Ph.d.

20090258054 - Heparin prodrugs and drug delivery stents formed therefrom: A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a... Agent: Squire, Sanders & Dempsey LLP

20090258055 - Heparin prodrugs and drug delivery stents formed therefrom: A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a... Agent: Squire, Sanders & Dempsey LLP

20090258053 - Medical stent provided with a combination of melatonin and paclitaxel: A stent provided with a composition comprising melatonin and paclitaxel is described. The described stent is useful in treating smooth muscle cell proliferation, such as stenosis and preventing restenosis in vascular vessels.... Agent: Knobbe Martens Olson & Bear LLP

20090258051 - Microbes encapsulated within crosslinkable polymers: The invention relates to porous films comprising crosslinked electrospun hydrogel fibers. Viable microbes are encapsulated within the crosslinked electrospun hydrogel fibers. The crosslinked electrospun hydrogel fibers are water insoluble and permeable. The invention also relates to methods of making and using such porous films.... Agent: Brookhaven Science Associates/ Brookhaven National Laboratory

20090258048 - Self-assembling monomers and oligomers as surface-modifying endgroups for polymers: Polymers having the formula R(LE)x wherein R is a polymeric core having a number average molecular weight of from 5000 to 7,000,000 daltons and having x endgroups, E is an endgroup covalently linked to polymeric core R by linkage L, L is a divalent oligomeric chain, having at least 5... Agent: Birch Stewart Kolasch & Birch

20090258056 - Systems and methods for preparing autologous fibrin glue: A method of regenerating tissue in a living organism. The method includes the act of contacting an affected area of the living organism with a solid-fibrin web, the solid-fibrin web comprising platelets that release growth factors about one minute after contact to regenerate the tissue in the living organism.... Agent: Michael Best & Friedrich LLP

20090258057 - Synthetically functionalized living cells: Uniform, functional polymer patches can be attached to a fraction of the surface area of living individual cells. These surface-modified cells remain viable after attachment of the functional patch. The patch does not completely occlude the cellular surface from the surrounding environment. Functional payloads carried by the patch may include,... Agent: Steptoe & Johnson LLP

20090258058 - Novel silicone film former for delivery of actives: The invention provides: a film-forming composition comprising a) a saccharide-siloxane copolymer; b) a crosslinking agent; c) one or more active/inactive ingredients; and d) optionally, a solvent, or solvent mixture, wherein the saccharide-siloxane copolymer has the following formula: R2aR1(3−a)SiO—[(SiR2R1O)m-(SiR12O)n]y-SiR1(3−a)R2a that is further formulaically defined and wherein the saccharide-siloxane copolymer is a... Agent: Dinsmore & Shohl LLP

20090258059 - Stabilized foam for medical psa substrate: The present invention provides a method for using a stabilized foam that is a crosslinked, closed cell polyolefin having a stabilizing layer and an adhesive layer. The method can be used for treating a wound, scrape, abrasion or skin puncture, for maintaining cleanliness of an operation incision site, suture site,... Agent: Charles N.j. Ruggiero Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20090258060 - Hydrogel compositions: Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer,... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090258061 - Once-a-day replacement transdermal administration of fentanyl: A method and a daily replacement patch for transdermally administering an opioid for analgesic effect. The patch is applied to a subject to deliver the opioid through the skin. The patch may be replaced daily and over an extended period of time.... Agent: Stoel Rives LLP - Slc

20090258063 - Transdermal patch: The present invention provides a transdermal patch having excellent preservation stability and transdermal absorbency of DMAEs. The patch has a support and a plaster layer integrally laminated on one surface of the support, and the plaster layer includes: DMAEs; an acrylic adhesive prepared by copolymerizing monomers respectively containing 30 to... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090258062 - Transdermal therapeutic system comprising active ingredient particles and having increased active ingredient flux: The invention relates to a transdermal therapeutic system, preferably a transdermal patch, having an active ingredient-containing matrix formed substantially of a water-insoluble base material, such as rubber and synthetic polymers, into which is incorporated water-soluble and/or water-swellable inclusion bodies, e.g. inclusion bodies formed from polyvinyl alcohol or polyethylene glycol, that... Agent: Propat, L.L.C.

20090258064 - Compositions of ucp inhibitors, fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and/or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination... Agent: Wolf Greenfield & Sacks, P.C.

20090258065 - Dermatological compositions comprising avermectin nanocapsules: Compositions and nanoemulsions containing lipid nanocapsules dispersed in a hydrophilic phase, such nanocapsules including at least one avermectin compound, are useful for the treatment of dermatological pathologies, e.g., rosacea.... Agent: Buchanan, Ingersoll & Rooney PC

20090258066 - Compositions comprising weakly basic drugs and controlled-release dosage forms: The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing a weakly basic drug core, a layer of alkaline buffer, and a controlled-release coating. The present invention is also directed to pharmaceutical dosage forms, including orally disintegrating tablets, conventional tablets, and capsules, and... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090258067 - Modified release composition of at least one form of venlafaxine: The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090258071 - Compositions and methods for ph targeted drug delivery: The invention provides compositions and methods for the targeted, in particular, pH targeted, delivery of pharmaceutically active agents in mammals. The compositions comprise pH sensitive diblock copolymers, which permit the release of the pharmaceutically active agent when exposed to an environment having a particular pH. The compositions are particularly useful... Agent: Goodwin Procter LLP Patent Administrator

20090258069 - Delivery of lfa-1 antagonists to the gastrointestinal system: The present invention provides compositions and methods for treating disorders and diseases by delivery of LFA-1 antagonists to the gastrointestinal system. Methods include delivery of LFA-1 antagonists to effect localized treatment.... Agent: Wilson, Sonsini, Goodrich & Rosati

20090258072 - Large ultraviolet attenuating pigments: Large particle sunscreen powders useful as ingredients in cosmetic compositions and in dispersions for incorporation into cosmetic compositions comprise a UV shielding agent in a matrix material. The macroparticle powders can be used in a wide range of cosmetic formulations, including sunscreens, eyeshadow, mascara, foundation, blusher, toner, lipstick and other... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090258073 - Magnetic carrier and medical preparation for controllable delivery and release of active substances, methods of their production and methods of treatment using thereof: The present invention relates to magnetic carriers and medical preparations for controllable delivery and release of active substances. The carrier for active substances comprises material A, which is magnetically or electrically sensible, and material B capable of controlling the retention/release rate of the said active substance from the said carrier,... Agent: Dr. Maria Nilova

20090258068 - Titanium oxide-zinc oxide aggregate powder and production method thereof: The present invention provides a powder that can display excellent protection ability in both UV-A and UV-B regions. The titanium oxide-zinc oxide aggregate powder comprises an aggregate formed by the aggregation of porous titanium oxide particles and zinc oxide particles, and said porous titanium oxide particle is an aggregate of... Agent: Rankin, Hill & Clark LLP

20090258070 - Topical lfa-1 antagonists for use in localized treatment of immune related disorders: This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for topical delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders... Agent: Wilson, Sonsini, Goodrich & Rosati

20090258074 - Mixtures of tannins, their production and use in medicaments or as disinfectants: i

20090258075 - Respiratory drug condensation aerosols and methods of making and using them: Described herein are respiratory drug condensation aerosols and methods of making and using them. Kits for delivering condensation aerosols are also described. The respiratory drug aerosols typically comprise respiratory drug condensation aerosol particles. In some variations the respiratory drug compound is selected from the group consisting of β-adrenergics, methylxanthines, anticholinergics,... Agent: Swanson & Bratschun, L.l.c

20090258076 - Water-soluble magnetic or metal oxide nanoparticles coated with ligands, preparation method and usage thereof: This invention provides water-soluble magnetic or water-soluble metal oxide nanoparticles, which are coated with phase transfer ligands having an adhesive region, an adhesive region-crosslinking region, or an adhesive region-reactive region, and also provides a method of preparing water-soluble magnetic or metal oxide nanoparticles, the method including (1) synthesizing water-insoluble magnetic... Agent: Holme Roberts & Owen LLP

20090258078 - Antioxidant polymer nanocarriers for use in preventing oxidative injury: The present invention is a method for encapsulating active protein in a polymeric nanocarrier. The instant method employs homogenization at subzero temperatures so that enzyme activity is retained. Enzymes which can be encapsulated by the present method include, for example, antioxidant enzymes and xenobiotic detoxifying enzymes. Encapsulation of an enzyme... Agent: Howson & Howson LLP

20090258077 - Composition and method for treating or preventing white spot syndrome virus: The present invention relates to a composition and method for treating or preventing white spot syndrome virus of arthropod. The present invention is based on using Artemisia japonica extract, and preferably, a mixture of Artemisia japonica extract and Saururus chinensis extract as effective agent. More preferably, the present invention provides... Agent: Jones Day

20090258079 - Biocompatible block copolymer, use thereof and manufacturing method thereof: A biocompatible block copolymer having a hydrophobic segment composed of amino acid and hydroxycarboxylic acid and a hydrophilic segment composed of polyalkylene oxide, wherein the terminal not bonded to the hydrophilic segment of the hydrophobic segment is composed of an amino acid unit.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090258080 - Emu oil and fruit composition: A composition is provided comprising emu oil and processed whole fruit. The composition is in a form for either topical application to human skin or for internal ingestion.... Agent: Mcgarry Bair PC

20090258081 - New plant derived seed extract rich in essentially fatty acids derived from salvia hispanica l. seed: composition of matter, manufacturing process and use: A Salvia hispanica L. derived seed oil extract composition of matter containing from 60-88% PUFAs in a ratio of from 3.1:1-3.3:1 of ALA to LA, 4-100% of C-18 mono-unsaturated fatty acid, 1-5% of C-18 saturated fatty acid and 4-8% of C-16 saturated fatty acid in a mixed triglyceride form stable... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.

20090258082 - Dried amnion and method for drying teatment of amnion: The present invention provides a dried amnion which is dried with maintaining tissues of a raw amnion and can be easily stored for a prolonged period of time. An amnion which is dried with maintaining cells and tissues of a raw amnion can be produced by repeating a pressure-reducing operation... Agent: Birch Stewart Kolasch & Birch

20090258085 - Emulsions and methods of their production: An emulsion including Dead Sea water is provided, as well as methods for making and using such an emulsion. The emulsion can also include a structured surfactant.... Agent: The Nath Law Group

20090258083 - Method of producing and applications of composition of hypochlorous acid: A method for preparing a stabilized antimicrobial hypochlorous acid solution by diluting an aged stock solution to provide a hypochlorous acid solution at a concentration of about 50 to about 7000 ppm at a pH range of about 2.8 to about 4.0. The antimicrobial hypochlorous acid solution maintains at least... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20090258084 - Mono and combination therapy with a m1/m4 muscarinic agonist (sabcomeline) for treatment of cognitive disorders in schizophrenia: The invention relates to the use of a functional muscarinic M1/M4 receptor agonist such as the functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof, in particular sabcomeline or a pharmaceutically acceptable salt thereof in for the treatment of cognitive impairment in schizophrenia and to combination therapies for... Agent: Nixon & Vanderhye, PC

20090258086 - Biofilm extracellular polysaccharide solvating system: The invention provides a solvating system for the removal of biofilms which solvates the extracellular polysaccharide matrix holding it to a surface. The aqueous solvating system comprises water, a metal ion sequestering agent, and a solvating agent for an extracellular polysaccharide matrix, which is gentle enough to be used directly... Agent: Iplm Group, P.A.

20090258087 - Method to increase and accelerated rehabilitate the capacity for work: The method to increase and accelerated rehabilitate the capacity for work is characterized in that the person is exposed to gaseous products having the property to improve physical and psychological human capabilities during a period of preparing for extreme strains and/or after extreme strains; the exposure to gaseous products is... Agent: The Nath Law Group

20090258088 - Use of materials and external stimuli for synovectomy: This invention has as one of its aspects a method to provide a safe an effective treatment for synovectomy. The method involves the administration a material to the affected joint, allowing the material to localize in the synovial membrane, and then applying an external stimulus that interacts with the material... Agent: Karen L. Kimble Technology Law, PLLC

20090258089 - Chemo- and radiation-sensitization of cancer by antisense trpm-2 oligodeoxynucleotides: Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal... Agent: Larson & Anderson, LLC

20090258090 - Colon cleansing solution: The field of colonic diagnostic and surgical procedures is hampered by the lack of optimal means available to cleanse the colon. A compromise between convenient, distasteful, solid or low volume, hyperosmotic solutions which cause considerable fluid and electrolyte imbalances in patients and large volume, difficult to consume, iso-osmotic solutions has... Agent: Wilmerhale/boston

20090258091 - Compositions and methods for treating neurodegenerative diseases: The present invention relates to compositions and methods for treating neurodegenerative diseases. In some embodiments, the present invention provides compositions for treating and preventing presbycusis.... Agent: Casimir Jones, S.c.

20090258092 - Improved tissue maintenance: The invention provides a method of reducing damage to a tissue, organ or cell from surgical procedures comprising administering a composition comprising a potassium channel opener/agonist and/or an adenosine receptor agonist (eg. adenosine) together with a local anaesthetic (eg. lignocaine) when perfusing the organ.... Agent: Venable LLP

20090258093 - Use of a brassocattleya marcella koss orchid extract as an active agent to prevent or delay the appearance of signs of cutaneous aging: The present invention describes the use of an extract from the Brassocattleya marcella Koss orchid, in a cosmetic composition or for the preparation of a cosmetic composition, as a hydrating and/or anti-aging agent designed to prevent or delay the appearance of signs of intrinsic or extrinsic aging of the skin,... Agent: Foley And Lardner LLP Suite 500

20090258094 - Xanthohumol-enriched hop extract: A method for preparing a xanthohumol-rich hop composition. The method includes providing a solution that contains xanthohumol-containing hop substances and effecting precipitation of non-xanthohumol hop substances by adjusting both the salt concentration and pH value of the solution. The xanthohumol-rich hop composition prepared by this method can be used for... Agent: Edwards Angell Palmer & Dodge LLP

20090258095 - Use of a ginkgo biloba extract for the treatment of mitochondrial disease of genetic origin: The invention relates to the use of Ginkgo biloba for the treatment of mitochondrial diseases of genetic origin and more particularly mitochondrial encephalomyophathies.... Agent: Hunton & Williams LLP Intellectual Property Department

20090258096 - Anticancer methods employing extracts of gleditsia sinensis lam: Selective apoptotic extracts of Gleditsia sinensis Lam are provided. Also provided are methods of using said extracts to induce apoptosis in specific cells, especially in a human. Provided as well are uses of the extracts of Gleditsia sinensis Lam for the preparation of a medicament for the selective induction of... Agent: Wilson, Sonsini, Goodrich & Rosati

20090258097 - Extracts and compounds from \"agapanthus africanus\" and their use as biological plant protecting agents: The invention relates to plant extracts, especially based on species of the genus Agapanthus and combinations thereof with other extracts deriving from other plants. The invention further relates to the isolation, purification and identification of compounds in these extracts. The plant extracts and the isolated substances show significant antimicrobial activity,... Agent: Arent Fox LLP

20090258098 - Penetrating carrier, antifungal composition using the same and method for treatment of dermatophyte infections: An antifungal composition and penetrating carrier system for topical treatment of dermatophytic infection and secondary bacterial infections. The antifungal composition includes various fungistatic and fungicidal essential oil components, or combinations thereof. The penetrating carrier system may include various ingredients, including a penetration enhancer, such as isopropyl myristate.... Agent: David B. Tingey

20090252673 - Methods of making and using rubidium-81-containing compositions: The present invention relates to preparation of imaging compositions containing Rubidium-81. In addition, the present invention relates to uses of Rubidium-81-containing compositions in diagnostic imaging such as, for example, myocardial imaging.... Agent: Mallinckrodt Inc.

20090252672 - Nasal delivery of therapeutic agents using tight junction agonists: The invention relates to a therapeutic composition comprising a therapeutically effective amount of one or more therapeutic agents and a nasal mucosa absorption-enhancing amount of one or more tight junction agonists. The invention further relates to a method of treating a subject comprising intranasally administering the composition of the invention... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090252676 - N-alkoxyamide conjugates as imaging agents: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging... Agent: Wolf Greenfield & Sacks, P.C.

20090252677 - Probes for in vivo targeting of active cysteine proteases: Activity-based probes, which are specific for certain active cysteine proteases (caspase, cathepsin and legumain) and carry radioactive labels, are disclosed. The present probes comprise an acyloxymethyketone (AOMK) “warhead” that binds only to active enzyme. The probes further comprise peptide-like structure that targets the probe to a specific cysteine protease or... Agent: Peters Verny , L.L.P.

20090252675 - Radionuclide therapy for urinary bladder cancer: The compounds used in this method for the treatment of bladder cancer comprise a radioisotope particle emitter, such as alpha- or beta-emitters or low energy gamma-emitters, associated with a chelating agent (for metallic radioisotopes) or other compound (by covalent bond for iodine or other non-metals) selected such that these permit... Agent: Technology Law, PLLC

20090252674 - Tripodal ligands with the coordinating motifs k2 -bh2 or k3 -bh3 relevant for biomedical applications of organometallic complexes: The present invention relates to a compound for use as a chelator in the radioactive labeling of biomolecules with metal tricarbonyl complexes, which compound has the general Formula (I) wherein M is a monovalent cation, such as Li, Na, K, Tl, Rb, Cs or an alkyl ammonium; R1 is H,... Agent: Mallinckrodt Inc.

20090252678 - Cox-2-targeted imaging agents: The presently disclosed subject matter provides a method for synthesizing a radiological imaging agent by reacting a COX-2-selective ligand with a compound comprising a detectable group, wherein the COX-2-selective ligand is a derivative of a non-steroidal anti-inflammatory drug (NSAID) comprising an ester moiety or a secondary amide moiety. Also provided... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090252679 - Novel compound having affinity for amyloid: wherein A1, A2, A3 and A4 independently represents a carbon or nitrogen; R1 is a halogen substituent; R2 is a halogen substituent; and m is an integer of 0 to 2, provided that at least one of R1 and R2 is a radioactive halogen substituent, at least one of A1,... Agent: Fitch, Even, Tabin & Flannery

20090252680 - Novel compound with affinity for amyloid: wherein each of A1, A2, A3 and A4 independently represents a carbon or nitrogen; R1 is a group selected from the group consisting of hydrogen, hydroxyl group, carboxyl group, sulfuric acid group, amino group, nitro group, cyano group, non-radioactive halogen substituents, alkyl substituents with 1-4 carbon atoms and alkoxy substituents... Agent: Fitch, Even, Tabin & Flannery

20090252682 - In-vivo optical imaging method including analysis of dynamic images: In-vivo optical molecular imaging methods for producing an image of an animal are described. A time series of image data sets of an optical contrast substance in the animal is acquired using an optical detector Each image data set is obtained at a selected time and has the same plurality... Agent: Occhiuti Rohlicek & Tsao, LLP

20090252681 - Nanobodies and polypeptides against egfr and igf-ir: The invention relates to polypeptides and Nanobodies against Epidermal Growth Factor Receptor (EGFR) and/or Insulin Growth Factor-I Receptor (IGF-IR). The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or... Agent: Wolf Greenfield & Sacks, P.C.

20090252683 - Composition comprising cross-species-sepecific antibodies and uses thereof: The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of... Agent: Foley And Lardner LLP Suite 500

20090252684 - Determination of tissue-specific profile of amino acid requirements form the relationship between the amounts of trnas for individual amino acids and the protein-bound amino acid profile of the tissue: Systems and methods by which optimal profiles of amino acids for specific tissues can be determined. The results of these systems and methods can then be sued to generate medical nutrition products targeting specific tissues either to enhance growth of specific tissues by providing complementary amino acids in a nutritional... Agent: Lewis, Rice & Fingersh, Lc Attn: BoxIPDept.

20090252685 - High penetration prodrug compositions of prostaglandins and related compounds: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of prostaglandins or prostaglandin analogs which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent prostaglandins or prostaglandin analogs after crossing the biological barrier and... Agent: Perkins Coie LLP

20090252686 - Ex vivo hyperpolarization of imaging agents: The present invention generally relates to methods for accelerating the ex vivo induction of nuclear hyperpolarization in imaging agents.... Agent: Choate, Hall & Stewart/harvard University

20090252688 - Magnetic resonance contrast medium containing an iron-binding protein: An inventive principle of at least one embodiment is based on linking an iron-binding functionality in the form of a bacterial iron-binding protein to a binding element which specifically recognizes a biological structure, in order to increase a local detectable increase in the concentration of the contrast medium. In at... Agent: Harness, Dickey & Pierce, P.L.C

20090252687 - Asymmetric fluoro-substituted polymethine dyes: The present invention relates to improved conjugates of biological molecules with an improved class of water-soluble, green to near infra-red (NIR) cyanine labelling dyes. The dyes are asymmetric fluoro-substituted polymethines, and exhibit a high degree of photostability and reduced dye-dye quenching, as well as a high fluorescence quantum yield. The... Agent: Ge Healthcare, Inc.

20090252689 - Hair styling composition: e

20090252690 - Flavoured mouth wash composition: The present invention provides a flavoured product comprising four or more flavour materials having antimicrobial properties and selected from the group comprising nonanol, decanol, nonanal, decanal, amyl propionate, anethole synthetic, anisic aldehyde, basil oil, benzyl benzoate, benzyl butyrate, benzyl formate, chamomile oil, cinnamic aldehyde, cis-3-hexenol, clove bud oil, damascone, ethyl... Agent: Morgan Lewis & Bockius LLP

20090252692 - Esterified fatty acid composition: The invention is directed to compositions comprising lecithin, olive oil, esterified fatty acids and mixed tocophenols for use in the treatment and prevention of various types of arthritis and other inflammatory joint conditions, periodontal diseases and psoriasis, which avoid many of the side effects associated with known treatments. The compositions... Agent: Techlaw LLP

20090252691 - Foam manipulation compositions containing fine particles: A foam manipulation stabilizing composition for use in consumer products includes a plurality of surface-modified particles in combination with at least one surfactant. The particles have an average particle size greater than 100 nm up to about 50 μm and a hydrophobicity measured by a contact angle between about 20°... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090252693 - Process for preparing dispersions of tio2 in the form of nanoparticles, and dispersions obtainable with this process and functionalization of surfaces by application of tio2 dispersions: A process for preparing nanoparticulate dispersions of TiO2 in crystalline anatase form and the dispersions obtained with the process, useful for preparing photocatalytic coatings on surface and the photocatalytic decontamination of gas and liquids.... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20090252694 - Novel chalcone derivatives, pharmaceutically acceptable salt, method for preparation and uses thereof: Disclosed relates to a novel chalcone derivative, pharmaceutically acceptable salt thereof, a method for preparing the same and uses thereof, the chalcone derivative being readily obtained through the steps of: reacting aminoacetophenone with sulfonylchloride under the presence of an appropriate salt; and reacting the compound prepared in the above step... Agent: Lucas & Mercanti, LLP

20090252695 - Special effects with mixtures of interference pigments: A method of producing mixtures of interference pigments having special effects comprises mixing at least one large particle size interference pigment with at least one normal size interference pigment of predetermined colors and in proportions desired to obtain a unique effect.... Agent: Millen, White, Zelano & Branigan, P.C.

20090252696 - Hair straightening composition comprising urea: An aqueous based hair straightening composition having a pH from 12 to 14 comprising i) an hydroxide ion generator; and ii) from 0.5 wt % to 20 wt % of the total composition of urea in which the weight ratio of urea to hydroxide generator is greater than 1:1.... Agent: Unilever Patent Group

20090252697 - Method for permanently reshaping keratin fibers with an acid pre-treating composition: A method for permanently reshaping keratin fibers, such as hair, comprising applying onto the keratin fibers a pre-treating composition comprising, in a cosmetically acceptable medium, at least one entity chosen from non reducing inorganic acids, non reducing organic acids, and salts thereof, wherein the pH value of said pre-treating composition... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090252698 - Emulsion compositions for eyelashes: The invention relates to emulsion compositions for application to eyelashes containing at least one surfactant comprising silicone, hydrocarbon and glycerol group(s), as well as to methods of applying such compositions to eyelashes and kits containing such compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090252699 - Medical devices with an antimicrobial polyurethane coating: The present invention relates to a medical device comprising a coating which is obtainable starting from a solution comprising a nonionic polyurethaneurea and silver.... Agent: Connolly Bove Lodge & Hutz, LLP

20090252700 - Hydroxyphenyl cross-linked macromolecular network and applications thereof: A synthetic nucleus pulposus is provided that is useful in treatment of degenerative disc disease, augmentation of a degenerate disc, and alleviation of back pain. In an embodiment the synthetic nucleus pulposus comprises hyaluronan macromolecules that have been cross-linked via dihydroxyphenyl linkages. The synthetic nucleus pulposus restores or improves the... Agent: Pearne & Gordon LLP

20090252701 - Biostatic polymer: Methods and compositions effective for at least a week for prevention of microbial colony growth on a surface, for example an inanimate surface, where the surface is covered with a dry or substantially dry film formed from a composition comprising a polyvinyl alcohol and a quaternary ammonium compound. The film... Agent: Wolf Greenfield & Sacks, P.C.

20090252702 - Polymer-based anti-cancer agents: The present invention relates to the use of amphiphilic block copolymers for treating and preventing cancer, and in particular by reducing the proliferation rate of cancer cells. Preferred block copolymers comprises a central hydrophobic chain, preferably a polypropylene oxide chain, two which at least two hydrophilic side chains, preferably polyethylene... Agent: Young & Thompson

20090252705 - Il-6/il-6r fusion protein: The present invention relates to a fusion protein comprising a functional IL-6 molecule and a functional DS-sIL-6R molecule. The present invention also relates to a nucleic acid encoding the fusion protein, methods of producing the fusion protein, and the use of the fusion protein in the treatment of infectious diseases... Agent: Banner & Witcoff, Ltd.

20090252704 - Therapies for cognition and learning enhancement: The invention relates to a combination comprising an amount of an NO donor, such as ISDN, and/or an amount of another pharmaceutical agent that enhances neurotransmission or which acts as neuroprotectants such as memantine, clomethiazole and tacrine. These compositions can be used in producing cognition and learning enhancement, whereby the... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090252703 - Use of alcohol co-solvents to improve pegylation reaction yields: Disclosed is a method of producing a composition of matter. The method involves obtaining a pharmacologically active peptide; and conjugating the peptide to a pharmaceutically acceptable polyethylene glycol (PEG) by reacting the peptide with a PEG-aldehyde compound at a free amine moiety on the peptide in a buffer solution comprising... Agent: Amgen Inc.

20090252706 - Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer: The invention relates to compounds of formula (I) wherein Ra is —C(O)ORI, in which R1 is 1-7C-alkyl. 3-7C-cycloakyl, 1-7C-alkyl substituted by Raa, or 2-7C-alkyl substituted by Rab and Rac on different carbon atoms, Rb is -T-Q, in which T is 1-6C-alkylene or 3-7C-cycloalkylene, and Q is substituted by Rba and... Agent: Millen, White, Zelano & Branigan, P.C.

20090252707 - Novel expression vectors and uses thereof: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a... Agent: Buchanan, Ingersoll & Rooney PC

20090252714 - Autoantigenes for improved diagnosis, prognosis and treatment of inflammatory neurological diseases: According to the invention, autoantibodies, the appearance of which is characteristic of neurological autoimmune diseases, especially multiple sclerosis, are detected and the respective autoantigens identified. It can further be shown that many of these autoantigens are expressed specifically in the brain. The identification of the autoantigens and autoantibodies is useful... Agent: Mcandrews Held & Malloy, Ltd

20090252713 - Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy: A circular DNA molecule, useful for gene therapy, comprising at least one nucleic acid sequence of interest, characterised in that the region allowing the replication thereof has an origin of replication with a functionality in a host cell that requires the presence of at least one specific protein foreign to... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090252715 - Immortalization of mammalian cells: Genomic instability in T antigen expressing cells can be overcome by modifying the gene expressing T antigen so that it lacks Bub1 binding. Stable cell lines can be produced by incorporation of the modified T antigen gene, preferably together with the catalytic sub-unit of the telomerase construct.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090252708 - Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof: Biotherapeutic compositions of a non-pathogenic bacterial strain such as M-17 and its substrains and an anaerobic bacterial antibiotic such as metronidazole, are disclosed. Further disclosed are uses of M-17 or its substrains and an anaerobic bacterial antibiotic for treating disorders caused by anaerobic bacteria, whereby such disorders include, for example,... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090252709 - Novel bacterium belonging to the genus bifidobacterium and utilization of the same: It is intended to provide Bifidobacterium bifidum which has an effect of killing Helicobacter pylori and shows high survivability even in the case of being stored in a fermented milk food or drink under aerobic condition. The Bifidobacterium bifidum has the following characteristics: (1) having an effect of killing Helicobacter... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090252712 - Chimeric c3-like rho antagonist bone therapeutic: Methods of treating bone disorders in a subject in need thereof by administering to said subject a therapeutically effective amount of a Rho antagonist are disclosed.... Agent: Wilmerhale/boston

20090252711 - Stem cells and methods of making and using stem cells: The invention provides a method of making a pluripotent stem cell from a cell that is not pluripotent, such as from a differentiated stem cell or a lineage-restricted stem cell. The methods comprise culturing the starting cell in the presence of one or more epigenetic altering agents, such as a... Agent: Casimir Jones, S.c.

20090252710 - Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of... Agent: Jones Day

20090252716 - Methods for identifying nuclear receptor/ligand combinations for targeting brain tumor stem cells and for their use: An in vitro method is provided for identifying nuclear receptors abnormally expressed by brain tumor stem cells and a corresponding ligand which, if administered to brain tumor stem cells (BTSC's), is capable of inhibiting cell proliferation. Once the nuclear receptor/ligand combination has been identified, it can be utilized in vitro... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20090252717 - Compositions and methods for treating polyglutamine-expansion neurodegenerative diseases: The invention relates to methods for stimulating fast axonal transport in polyglutamine expansion diseases and treating polyglutamine expansion diseases by inhibiting SAPK-dependent phosphorylation of kinesin. The present invention also provides methods for identifying agents which inhibit the phosphorylation of the kinesin, as well as methods for monitoring treatment of a... Agent: Licata & Tyrrell P.C.

20090252718 - Phospholipase(s) and use(s) thereof: The invention relates to phospholipase(s), isoforms, derivatives, mutants and/or fragments thereof, for the preparation of a medicament for the treatment and/or prevention of ischemia. Preferred is the use of secretory phospholipase, particularly phospholipase A2, and even more particularly phospholipase A2 derived from the snake venom of Naja sputatrix... Agent: Dickstein Shapiro LLP

20090252719 - Use of fructanases in feed of hoofed animals, preferably to prevent diseases: Laminitis is defined as an inflammation of the sensitive laminae of the hoof, especially in horses. It has been surprisingly found that fructanases such as 2,1-β-D-fructan hydrolase are highly effective as therapeutic and prophylactic agents against laminitis in horses. The fructanases may be used as enzyme compositions in horse feed,... Agent: Nixon & Vanderhye, PC

20090252720 - Prolonged fix analogues and derivatives: The invention is related to FIX analogues which have an increased circulation time in the blood stream before activation compared to that that of native FIX (and a week after injection to a patient retains at least about 5% of the FIX activity compared to the initial activity peak value... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090252722 - Botulinum neurotoxin a protein receptor and uses thereof: The invention relates to a polypeptide comprising an amino acid sequence, at least 70 percent of which are identical to the amino acid sequence of the synaptic vesicle glycoprotein of homo sapiens. Said polypeptide binds the HC fragment of botulinum neurotoxin A provided that the polypeptide is not the synaptic... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090252721 - Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer: The invention relates to agents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the invention relates to the use of nucleic and amino acid sequences encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin like protein (SYPL), stomatin like 2 (STOML2), Ras related GTP binding protein RAGA), nucleotide sensitive... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090252724 - Antibodies against amyloid beta 4 with glycosylated in the variable region: The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (VH). More specifically, a pharmaceutical and a diagnostic composition comprising said antibody molecule and antibody mixtures are... Agent: Stephen M. Haracz Bryan Cave

20090252726 - Antibodies for inhibiting blood coagulation and methods of use thereof: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:FVIIa complex, effectively preventing factor... Agent: Morrison & Foerster LLP

20090252727 - Glucagon receptor antagonists: The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that inhibit binding of glucagon to its receptor and their use in the treatment... Agent: Eli Lilly & Company

20090252723 - Remedy for endometriosis: The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.... Agent: Sughrue-265550

20090252725 - Use of cd23 antibodies to treat malignancies in patients with poor prognosis: The invention relates to methods of treating B-cell chronic lymphocytic leukemia, and other CD23+ malignancies, in patients with poor prognostic markers. The method comprises administration of an CD23 antibody, including for example, lumiliximab to a mammal that over expresses a poor prognostic marker. The method can also comprise administration of... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090252730 - Methods of treating skin disorders using an il-31ra antagonist: The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.... Agent: Zymogenetics, Inc. Intellectual Property Department

20090252728 - Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.... Agent: Agensys C/o Morrison & Foerster LLP

20090252729 - Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto: The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090252731 - Multivalent carriers of bi-specific antibodies: Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The... Agent: Immunomedics, Inc.

20090252734 - Antihuman alpha 9 integrin antibody and use of the same: The present invention relates to: an antibody (particularly a monoclonal antibody), a chimeric antibody, a humanized antibody and a human antibody, which specifically recognize human α9 integrin; a hybridoma cell which produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a... Agent: Ladas & Parry LLP

20090252733 - Generation and profiling of fully human gold-derived therapeutic antibodies specific for human cd38: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such... Agent: Foley And Lardner LLP Suite 500

20090252736 - Mammalian genes; related reagents: Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.... Agent: Schering-plough Biopharma Legal Department

20090252735 - Novel peptides for development of diagnostic and therapeutic agents and methods of using same: Novel immuno-interactive fragments of the αC portion of a mammalian inhibin α subunit, together with their variants and derivatives, produce antigen-binding molecules that are interactive with the αC portion, and which are chemically well defined and which can be produced in commercially significant quantities. The antigen-binding molecules of the invention... Agent: Panitch Schwarze Belisario & Nadel LLP

20090252737 - T cell regulatory genes and methods of use thereof: A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090252732 - Variable region sequences of il-31 monoclonal antibodies and methods of use: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by... Agent: Zymogenetics, Inc. Intellectual Property Department

20090252739 - Cerebral infarction suppressant: An objective of the present invention is to provide a suppressant for cerebral infarction occurred after long-term ischemia associated with actual cerebral infarction, and has fewer side effects. The cerebral infarction suppressant of the present invention is characterized in comprising an anti-HMGB1 monoclonal antibody as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090252738 - Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix: Compositions and methods useful in inhibiting proliferation of CA IX+preneoplastic or neoplastic cells in a mammal are provided. The compositions are antagonist anti-CA IX antibodies and other inhibitory agents that target carbonic anhydrase activity of CA IX on these cells. The antagonist anti-CA IX antibodies or antigen-binding fragments thereof are... Agent: Novartis Vaccines And Diagnostics Inc.

20090252740 - Method for predicting responsiveness to tnf alpha blocking agents: The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with a TNFα blocking agent, which method comprises determining the expression level of eight genes in a biological sample of said patient, wherein said genes are EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12,... Agent: Occhiuti Rohlicek & Tsao, LLP

20090252741 - Human monoclonal anti-ctla4 antibodies in cancer treatment: Although results from preclinical studies in animal models have proven the concept for use of anti-CTLA-4 antibodies in cancer immunotherapy, two major obstacles have hindered their successful application for human cancer therapy. First, the lack of in vitro correlates of the anti-tumor effect of the antibodies makes it difficult to... Agent: Calfee Halter & Griswold, LLP

20090252743 - Anti-tnf antibodies, compositions, methods and uses: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha... Agent: Philip S. Johnson Johnson & Johnson

20090252742 - Il3ralpha antibody conjugates and uses thereof: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells)... Agent: Jones Day

20090252744 - Methods for treating bone cancer pain by administering a nerve growth factor antagonist antibody: The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF.... Agent: Pfizer Inc. Patent Department

20090252745 - Amino acids in the hcv core polypeptide domain 3 and correlation with steatosis: The presently disclosed subject matter provides methods and compositions for predicting a tendency of a subject infected with hepatitis C virus (HCV) to develop steatosis. In some embodiments, the disclosed methods include the steps of (a) isolating from the subject a biological sample comprising an HCV Core polypeptide or a... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090252746 - Erythropoietin receptor binding antibodies: The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies.... Agent: Paul D. Yasger Abbott Laboratories

20090252747 - Nucleic acids and corresponding proteins entitled 282p1g3 useful in treatment and detection of cancer: A novel gene 282P1G3 and its encoded protein, and variants thereof, are described wherein 282P1G3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 282P1G3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 282P1G3 gene or... Agent: Agensys C/o Morrison & Foerster LLP

20090252748 - Sp35 antibodies and uses thereof: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090252750 - Antibodies and immunotoxins that target human glycoprotein nmb: The invention provides high affinity antibodies suitable for forming immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells.... Agent: Banner & Witcoff, Ltd.

20090252749 - Compositions and methods for producing a composition: The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090252751 - Immune adjuvant comprising ubiquinone: This invention relates to an immunoadjuvant, which has an excellent antibody production enhancing function and is highly safe, and a vaccine composition comprising the immunoadjuvant. More specifically, the present invention relates to an immunoadjuvant comprising a ubiquinone represented by formula (I), and a vaccine composition comprising the ubiquinone represented by... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090252753 - Immunomodulation for autoimmune type-2 diabetes: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.... Agent: Cohen & Grigsby, P.C.

20090252752 - Kdr peptides and vaccines comprising the same: The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell... Agent: Townsend And Townsend And Crew, LLP

20090252754 - Vaccines containing the hiv tat protein as an adjuvant for the enhancement of cytotoxic t-cell responses: Tat, when used in a vaccine, causes MHC-I to expose subdominant epitopes present within an antigen, thereby enabling an optimal immune response to be generated, within an individual, against the antigen and variants of the antigen, such as might be encountered with HIV or influenza viruses.... Agent: Foley & Lardner LLP

20090252755 - Cloned genome of infectious hepatitis c virus strain hc-tn and uses thereof: Embodiments described herein include nucleic acid sequences, which encode hepatitis C virus of strain HC-TN, genotype 1a, proteins and polypeptides and fragments thereof. Use of these compositions, and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV are also contemplated.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090252756 - Protein-based streptococcus pneumoniae vaccines: Vaccine compositions and methods for protecting a mammalian subject against infection with S. pneumoniae are disclosed. The vaccines and methods comprise an effective amount of one or more Streptococcus pneumoniae cell wall and/or cell membrane proteins and/or immunogenically-active fragments, derivatives or modifications thereof, wherein said proteins are selected from a... Agent: Winston & Strawn LLP Patent Department

20090252757 - Methods and compositions for inhibiting hiv infection: This invention provides novel HIV-interacting host factors. The invention also provides methods of using the HIV-interacting host factors to screen for compounds that inhibit HIV infection. The methods comprise first screening test compounds for modulators of an HIV interacting host factor disclosed herein, and then further screening the identified modulating... Agent: Genomics Institute Of The Novartis Research Foundation

20090252758 - Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance: A mixture is formulated that is capable of improving a person's well being, lowering the risks of cardiovascular and/or Alzheimer's diseases and/or lowering blood sugar using natural and synthetic ingredients. A mixture of the present invention may be used as a food, a drink, a supplement or potentially a drug.... Agent: Haynes And Boone, LLPIPSection

20090252759 - Immunogenic composition: The present application relates to an immunogenic composition comprising at least 2 conjugates of N. meningitidis capsular saccharide and protein carrier, wherein said conjugates comprise at least 2 different N. meningitidis capsular saccharides selected from the group consisting of MenA, MenC, MenY and MenW, wherein at least one capsular saccharide... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090252760 - Construction of recombinant adenovirus with genes that codify for sag1, sag2 and sag3: This invention refers to the construction of recombinant adenovirus with genes that codify for T. gondii SAG1, SAG2 and SAG3, through a homologue recombination technique between two vectors. A first vector that serves as transference vector of genes and a second vector that bears the adenoviral receptor genome of these... Agent: David H. Voorhees Merek, Blackmon & Voorhees

20090252761 - Papilloma virus vaccine: A method of providing papilloma virus like particles which may be used for diagnostic purposes or for incorporation in a vaccine for use in relation to infections caused by papilloma virus. The method includes an initial step of constructing one or more recombinant DNA molecules which each encode papilloma virus... Agent: Foley And Lardner LLP Suite 500

20090252762 - novel proteosome-liposaccharide vaccine adjuvant: An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type... Agent: Seed Intellectual Property Law Group PLLC

20090252763 - Biological adjuvants: A method of enhancing uptake of DNA by a host cell line comprises introducing the DNA into the host cell and contacting the host cell with non-infectious viral particles. The non-infectious particles may be L-particle or PREPS (pre-viral DNA replication envelope particles), for example, those derived from alpha herpesvirus.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090252764 - Suture line administration technique using botulinum toxin: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon... Agent: Allergan, Inc.

20090252765 - Bacille calmette-guerin (bcg)-based anti-atheroma vaccine and methods of use thereof: The invention relates to a recombinant Mycobacterium bovis which expresses at least one Chlamydophila pneumoniae antigen.... Agent: Alston & Bird LLP

20090252766 - Attenuated gram negative bacteria: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an... Agent: Frommer Lawrence & Haug

20090252770 - Non-digestible sugar-coated products and process: A method and composition are provided for coating a component to achieve colon-targeted delivery. A component is coated with a fructose-based non-digestible carbohydrate such as a inulin, fructo-oligosaccharide or neosugar. The coated component is orally administered to a monogastric animal. The non-digestible coating causes the composition to pass through the... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090252769 - Preventive and therapeutic vaccine for storke and neurological disorders: A method for producing therapeutic vaccine which consist of NMDA-NR1 subunit expressed in insect cells to produce recombinant protein and was encapsulated in poly(D-L-lactide-co-glycolic-acid) (PGLA) microparticles by solvent exchange and used for oral immunization. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid... Agent: Jeeri R. Reddy

20090252768 - Use of stilbene derivatives for treatment and prevention of aquatic mold infections: The invention relates to methods of treatment and prevention of aquatic mold infections in aquatic organisms and methods of disinfecting equipment used in raising aquatic organisms. The methods comprise use of one or more stilbene derivatives, including 4,4′-bis-(1,3,5-triazinylamino)stilbene-2,2′-disulfonic acid derivatives.... Agent: Fennemore Craig

20090252767 - Water dispersible enteric coating formulation of nutraceutical and pharmaceutical dosage forms: The present invention relates to formulations for use as enteric coatings. More particularly, the present invention relates to a formulation comprising a dry blend of food grade ingredients that can be readily dispersed in water. This dispersion exhibits low viscosity and can easily be coated onto solid dosage forms through... Agent: Hercules Incorporated Hercules Plaza

20090252773 - Emulsion composition: An emulsion composition of the present invention includes (A) a salt of a higher fatty acid ester of ascorbic acid-2-phosphoric acid ester, (B) a polyglycerin fatty acid monoester including polyglycerin having a mean polymerization degree of 8 to 12 and an unsaturated fatty acid residual group of 14 to 22... Agent: Sughrue Mion, PLLC

20090252771 - Method for obtaining o/w cosmetic emulsions with high water resistance: This invention relates to a method for obtaining cationic O/W emulsions designed for skin care, which present high water resistance associated with excellent “skin feeling” characteristics.... Agent: Birch Stewart Kolasch & Birch

20090252772 - Pearlescent pigments coated with mixed inorganic/organic layers and method for the production thereof: i

20090252774 - Powder surface-treated with an organopolysiloxane having carboxyl groups, a dispersion of the same, and a cosmetic comprising the same:

20090252775 - Virucidal disinfectant: A virucidal disinfectant having broad-range activity includes an acidic phosphorus compound and/or salt thereof, an alcohol, and one or more polyalkylene glycols. The disinfectant, which may also kill bacteria and/or fungi, may be used for the hygienic disinfection of animate and inanimate surfaces. The invention also provides a disinfection method... Agent: Ratnerprestia

20090252776 - Animal deterrent for protecting plants: The invention provides materials, compositions, methods, and kits for deterring or repelling animals from eating plant materials. The invention relates to the use of particulate matter to deter animals from eating plant materials that are susceptible to grazing by animals. In exemplary embodiments, an adhesive is applied to target plant... Agent: Latimer, Mayberry & MatthewsIPLaw, LLP

20090252779 - Azaindazole compounds and methods of use: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.... Agent: Townsend And Townsend And Crew, LLP

20090252780 - Coatings for implantable medical devices: Coatings for implantable medical devices comprising non-fouling moieties or polymers chemically bonded to the surface of the device via chelating structures, and methods of fabricating the coatings are disclosed.... Agent: Squire, Sanders & Dempsey LLP

20090252777 - Method for formulating a controlled-release pharmaceutical formulation: Methods for making formulations of drugs and crystalline side chain polymers which formulations provide controlled and/or sustained release drug formulations.... Agent: Bell & Associates

20090252778 - Methods and devices for reducing tissue damage after ischemic injury: Methods and devices are provided for the delivery of therapeutic agents which reduce myocardial tissue damage due to ischemia and anti-restenotic agents which inhibit restenosis following a cardiac procedure such as stent implantation. The anti-ischemia agents are delivered to the myocardial tissue over an administration period sufficient to achieve reduction... Agent: Philip S. Johnson Johnson & Johnson

20090252781 - Hydrogel polymeric compositions and methods: Some aspects of this disclosure relate to a method of treating an opthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent.... Agent: Dardi & Asscociates, PLLC US Bank Plaza, Suite 2000

20090252782 - Transdermal preparations containing hydrophoic non-steroidal anti-inflammatory drugs: Disclosed is a transdermal preparation containing a hydrophobic drug. As a method of continuing the high drug permeation, it is used an unique hydrophilic polymer system in which the drug can be contained in a high concentration under no water environment, a solubility of the hydrophobic drug is decreased as... Agent: Merchant & Gould PC

20090252784 - Compositions comprising inhibitors of rna binding proteins and methods of producing and using same: Compositions for inhibiting RNA binding proteins, as well as methods of producing and using the same, are disclosed herein.... Agent: Dunlap Codding, P.C.

20090252785 - Endoplasmic reticulum targeting liposomes: Provided are compositions that include lipid particles, such as liposomes, that can fuse with the ER membrane of a cell. The lipid particles can also deliver a cargo, such as a therapeutic or an imaging agent, encapsulated inside the particles inside the ER lumen of the cell. The compositions can... Agent: Foley And Lardner LLP Suite 500

20090252783 - Means for inhibiting the expression of cd31: The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090252786 - Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a gaba receptor: The present invention relates to a method of preventing or treating in a subject a disorder characterized in a reduced GABA receptor function by administering to the subject a therapeutically effective amount of a pharmacologically active blood serum product obtainable by a method comprising electrostimulation of a non-human animal, withdrawal... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090252787 - Granular pharmaceutical compositions: Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient.... Agent: Dr. Reddy''s Laboratories, Inc.

20090252788 - Balsalazide formulations and manufacture and use thereof: The invention relates to formulations and dosage schedules of balsalazide. The invention further relates to methods of producing pharmaceutical formulations of balsalazide.... Agent: Edwards Angell Palmer & Dodge LLP

20090252789 - One step spray-drying process: Capsules encapsulating an active or functional ingredient are obtainable by a process in which a feed that includes this ingredient is dispersed in the form of drops in a spraying tower and exposed to a temperature in the range of −20° C. to 500° C. In the tower, a cloud... Agent: Winston & Strawn LLP Patent Department

20090252791 - Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug: Dosage forms for administering a triptan and a nonsteroidal anti-inflammatory drug are disclosed, including multilayered tablets and mini-tablets. These multilayered tablets can be in a side-by-side arrangement, can be inlayed, or one layer can completely surround another. These can be administered in a capsule or directly. Other formulations are also... Agent: Dr. Reddy''s Laboratories, Inc.

20090252790 - Tablet formulation: The present invention relates to a pharmaceutical fixed dose combination tablet comprising repaglinide and metformin. The present invention also provides a method of producing said tablet.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090252792 - method to reduce the symptoms of heartburn and gastro-oesophageal reflux disease (gerd) by specific polysaccharides: The invention is directed to the use of a specific group of polysaccharides for reducing the symptoms or heartburn and gastroesophageal reflux isease. In addition, a pharmaceutical preparation is provided comprising a specific group of polysaccharides having a high hydration rate, a high viscosity, and a high stability at low... Agent: Morrison & Foerster LLP

20090252793 - Pharmaceutical compositions: Oral dosage forms comprising oxcarbazepine which when administered to a patient display no food effect.... Agent: Novartis Corporate Intellectual Property

20090252794 - Tablet: The present invention provides a novel tablet with improved tablet appearance and improved swallowability. The tablet contains a pharmaceutically acceptable anion exchange resin represented by colestimide as an active ingredient, and has a visibility-resolved tablet edge.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090252795 - Bioceramic scaffolds for tissue engineering: This invention relates to bioinert microporous bioceramic scaffolding, matrices or spheres comprising a particulate microporous bioinert ceramic material, which is a primary structure, and in the form of scaffolds, matrices or spheres, having interconnected pores. Pores on the surface of the spheres, matrices or scaffolds are connected to pores inside... Agent: Stuart K. J. Smyth

20090252796 - Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance: A mixture (which may be utilized as a food or a drink or a supplement or a drug or a cosmetic or a hygienic product) that is formulated and is capable of improving a person's well being, lowering the risks of cardiovascular and/or Alzheimer's diseases and/or lowering blood sugar using... Agent: Haynes And Boone, LLPIPSection

20090252797 - Topical application of ivermectin for the treatment of dermatological conditions/afflictions: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective... Agent: Buchanan, Ingersoll & Rooney PC

20090252799 - Materials and methods for wound treatment: The subject invention pertains to materials and methods for stopping or decreasing the blood flow from an open wound or medical or surgical procedure. Compositions of the invention comprise a salt form of a cross-linked polyacrylic acid. In one embodiment, the composition comprises a sodium salt of a polyacrylic acid.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090252798 - Matrix-gel graft without cells: A cell-free graft contains (i) a cohesive, scaffold-forming matrix with open porosity containing a biologically and pharmaceutically acceptable material, and (ii) a gel of a biologically and pharmaceutically acceptable material. The cell-free graft is produced by (v) contacting the matrix with the gel, and (vi) drying the matrix-gel complex formed... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090252800 - Anisotropic nanocomposite hydrogel: Anisotropic nanocomposite hydrogel materials are created using a process in which a hydrogel-forming material is crosslinked in the presence of nanoscale cellulose and subsequently thermally cycled under an applied tensile strain. Such materials are capable of exhibiting high mechanical and viscoelastic anisotropy, increased stiffness when subjected to large strain, and... Agent: Dowell & Dowell P.C.

20090252802 - Compositions including relatively water insoluble/unwettable drugs and methods for using same: Compositions including therapeutic components and surfactant components which enhance the utility of the therapeutic components and methods of using such compositions are provided.... Agent: Allergan, Inc.

20090252803 - Glycyrrhetinic acid-mediated nanoparticles of hepatic targeted drug delivery system, process for preparing the same and use thereof: Disclosed are a hepatic targeted drug delivery system and a process for preparing the same. Also disclosed is a method for treating liver cancer.... Agent: James B. Conte Husch Blackwell Sanders LLP

20090252804 - Medical devices with an antibacterial polyurethaneurea coating: The present invention relates to a medical device which has at least one coating which is obtained starting from an aqueous dispersion, the aqueous dispersion comprising at least one nonionically stabilized polyurethaneurea and at least one silver-containing constituent.... Agent: Connolly Bove Lodge & Hutz, LLP

20090252801 - Process for the preparation of micronised sterile steroids: The present invention relates to a process for the preparation of micronised sterile steroids, comprising sterilisation of the steroids in crystalline form by means of irradiation with gamma or beta rays, and subsequent sterile micronisation.... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20090252805 - Film-coated and/or granulated calcium-containing compounds and use thereof in pharmaceutical compositions: Calcium-containing compounds have been at least partly film-coated and/or granulated with a water-soluble substance and a water-soluble polymeric substance and use of such coated compounds in pharmaceutical compositions. The at least partly film-coated and/or granulated calcium-containing compounds have proved suitable for the preparation of tablets having a very high load... Agent: Edwards Angell Palmer & Dodge LLP

20090252806 - Nanoparticulate tacrolimus formulations: The present invention is directed to nanoparticulate tacrolimus compositions. The composition comprising tacrolimus particles having an effective average particle size of less than about 2000 nm and at least one surface stabilizer.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20090252808 - Controlled release of biological entities: A process is provided for releasably encapsulating a biological entity. The process comprise combining a solution of a surfactant in a non-polar solvent with a precursor material and the biological entity to form an emulsion. The emulsion comprises a polar phase dispersed in a non-polar phase, wherein the polar phase... Agent: Foley And Lardner LLP Suite 500

20090252807 - Nanoparticulate and controlled release compositions comprising prostaglandin derivatives: The present invention is directed to compositions comprising a nanoparticulate prostaglandin derivative, preferably limaprost or a salt or derivative thereof, having improved bioavailability. The nanoparticulate prostaglandin derivative particles of the composition have an effective average particles size of less than about 2000 nm and are useful in the treatment of... Agent: Fox Rothschild, LLP Elan Pharma International Limited

20090252809 - Microcapsules from emulsion polymerization of tetraalkoxysilane: A process is disclosed for preparing microcapsules having a shell thickness of at least 18 nanometers by polymerizing a tetraalkoxysilane at the oil/water interface of an emulsion containing 0.1 to 0.3 weight percent of a cationic surfactant. The microcapsules are useful to prepare encapsulated sunscreens having sufficient robustness to prevent... Agent: Dow Corning Corporation Co1232

20090252810 - Aryl/alkyl succinic anhydride-hyaluronan derivatives: The present invention relates to the modification of hyaluronic acid (HA) with aryl/alkyl succinic anhydrides (ASA) to produce aryl/alkyl succinic anhydride HA derivatives, to the derivatives as such, and to their applications and uses, particularly in the cosmetic and biomedical industries. The ASA-HA derivatives are expected to have interesting properties... Agent: Novozymes North America, Inc.

20090252811 - Capped mesoporous silicates: The invention provides an article comprising, a mesoporous silicate matrix, such as a particle, having one or more pores; and one or more releasable caps obstructing one or more of the pores. The articles are useful as delivery vehicles for encapsulated agents such as therapeutic agents, polynucleotides, polypeptides and the... Agent: Schwegman, Lundberg & Woessner, P.A.

20090252812 - Use of fermented milk product for skin treatment: The use of a fermented milk product comprising non-hydrolysed whey proteins which is substantially free of casein proteins for the purpose of improving skin firmness, by structuring collagen without promoting collagen synthesis, when topically applied to skin is provided.... Agent: Norris, Mclaughlin & Marcus

20090252813 - Cercan: an energy supplement product for boosting the immune system: This invention concerns the process of creating an energy supplement product, good also as an anti-aging, aphrodisiac and as an alternative source to prevent or to remedy some diseases. The product is a composition of five ingredients: four marine animals (sea cucumber, sea urchin, sea sponge, and shark fin), and... Agent: Merek, Blackmon & Voorhees, LLC

20090252814 - Use of xenon for organ protection: Use of xenon is described. Xenon is used as an organ and/or tissue and/or cell protectant in the manufacture of a pharmaceutical for the protection from injury of organs and/or tissue and/or cells that express HIF.... Agent: Elmore Patent Law Group, PC

20090252815 - Pulverulent mixtures containing hydrogen peroxide and hydrophobized silicon dioxide: The present invention is directed to pulverulent mixtures comprising hydrogen peroxide and hydrophobized, pyrogenically prepared silicon dioxide powder, preferably with a methanol wettability of at least 40. The pulverulent mixtures exhibit good storage stability and can be used for the controlled release of hydrogen peroxide and/or oxygen. The invention also... Agent: Law Office Of Michael A. Sanzo, LLC

20090252816 - Inhalable gaseous medicament based on xenon and nitrous oxide: The invention concerns the use of a gaseous mixture containing gas xenon and gas nitrous oxide, and advantageously oxygen, for making all or part of an inhalable medicine for preventing or treating neurointoxication in a human. The xenon/nitrous oxide mixture of the invention acts on one or more cerebral receptors... Agent: Air Liquide Intellectual Property

20090252818 - Curcuma longa (turmeric) based herbal compound formulations as dietary supplements: Herbal compound formulations using herbs curcuma longa (turmeric), ocimum sanctum (holy basil) and emblica officinalis (amla) in their natural forms and a method of packaging the same for dietary supplement as tablets, wafers, capsules and as teabags where the packaging of individual dosages and the outer packaging may use visual... Agent: Tara Chand Singhal

20090252817 - Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances: The invention relates to methods for treatment and prevention of a metabolic imbalance, including diabetes mellitus and other related diseases or disorders, using an extract from a fruit of genus Elaeis.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West